STUDYID,USUBJID,SUBJID,SITEID,AGE,AGEU,SEX,RACE,RACEN,COUNTRY,COUNTRYC,REGION,REGIONN,SAFFL,ITTFL,HITTFL,TEVLFL,CAEVLFL,ARM,TRTP,TRTPN,TRTA,TRTAN,HENT1ST,HENT1STN,MHSEQ,MHTERM,MHDECOD,MHCAT,MHSCAT,MHBODSYS,MHSTDTC,MHENDTC,MHENRF
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CEREBRAL PALSY,Cerebral palsy,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",1939-12-29,,ONGOING
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LUNG CANCER,Lung neoplasm malignant,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2004-02-04,,BEFORE
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GASTRO-ENTEROSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-03-20,2011-03-20,BEFORE
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPOTHYREODISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1997,,ONGOING
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN -ABDOMEN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,WHIPPLES SURGERY,,PRIOR SURGERY,RESECTION,,2009-05-06,2009-05-06,BEFORE
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SILENT HEART ATTACK,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HEART BURN,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ATHEROSCLEROSIS,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,WHIPPLES SURGERY,,PRIOR SURGERY,RESECTION,,2010-07-14,2010-07-14,BEFORE
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HEARTBURN,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-10,,ONGOING
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SURGERY DUE TO ILEUS,Ileus,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-27,,BEFORE
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GASTRIC OUTLET OBSTRUCTION,Obstruction gastric,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-02,,ONGOING
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PANCREATIC DEFICIENCY,Pancreatic insufficiency,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-24,,ONGOING
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INSOMIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-07-18,,ONGOING
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEPHROSTOMY DUE TO HYDRONEPHROSIS.,Hydronephrosis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-09-09,,ONGOING
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,6.0,ERCP/STENTING,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-12-13,2011-12-13,BEFORE
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,7.0,EXPLORATORY SURGERY,,PRIOR SURGERY,EXPLORATORY,,2012-01-11,2012-01-11,BEFORE
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,3.0,MYOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,1994,,BEFORE
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-11,,ONGOING
CO-101-001,CO-101-001-001-010,01001010,001,65.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,4.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-01-11,,ONGOING
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1962,,BEFORE
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,POLYCYSTIC LIVER DISEASE,Polycystic liver disease,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",1998,,BEFORE
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1967,,BEFORE
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CYSTOPLASTY,Bladder repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008,,BEFORE
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,LEFT BLEPHAROPLASTY,Blepharoplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010,,BEFORE
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995,,BEFORE
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,SAPHENECTOMY,Phlebectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008,,BEFORE
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DUODENO-PANCREATECTOMY,,PRIOR SURGERY,RESECTION,,2007-05-21,2007-05-21,BEFORE
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,SINUSAL BRADYCARDIA,Sinus bradycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-01,,BEFORE
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANTHRACOSILICOSIS,Silicosis,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",,,ONGOING
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007-05-21,,ONGOING
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PROSTATIC ADENOCARCINOMA,Prostate cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2001-10-29,,BEFORE
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,COPD,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2001-01,,ONGOING
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PACE-MAKER IMPLANT,Cardiac pacemaker insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-03-04,,ONGOING
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,MESENTERIC BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-12-08,2011-12-08,BEFORE
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HEPATITIS B,Hepatitis B,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1976,,BEFORE
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIFFICULTIES TO FALL ASLEEP,Initial insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1971,,ONGOING
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,POST-MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,ONGOING
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LEFT HEMITHYROIDECTOMY,Thyroidectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1990,,BEFORE
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,INTERMITENT CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01,,ONGOING
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,APPENDICECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1968,,BEFORE
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1989,,BEFORE
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"CONTROLLED, NON SYMPTOMATIC, SUPRAVENTRICULAR EXTRASYSTOL",Supraventricular extrasystoles,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,POST-PRANDIAL ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PNEUMONIA,Pneumonia,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1948,,BEFORE
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INTERMITTENT BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1991,,ONGOING
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HYPERTENSIA,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,EPISODE OF GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-02,,BEFORE
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,COLONIC TUBULAR ADENOMA ABLATION,Colon adenoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2009,,BEFORE
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ALCOHOLISM,Alcoholism,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",,,ONGOING
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PNEUMOPATHY,Lung disorder,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1983,,BEFORE
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,VEINIOUS THROMBOSIS,Venous thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-02-12,,ONGOING
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03,,ONGOING
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,JAUNDICE,Jaundice,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-04-04,,BEFORE
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MANIA,Mania,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1970,,BEFORE
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PAIN (LEFT HYPOCHONDRIUM),Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,SUPERFICIAL GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARRHYTHMIA (RESOLVENT),Arrhythmia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,GASTROESOPHAGEAL REFLUX,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,EPIGASTRIC PAINS,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BENIGN PROSTATIC HYPERTROPHY,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,COPD,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PHLEBITIS,Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TACHYCARDIA,Tachycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CRYPTORCHIDISM,Cryptorchism,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",,,BEFORE
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,BEFORE
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,UROLITHIASIS,Calculus urinary,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,,,ONGOING
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,HEPATIC JEJUNOSTOMY AND LOOP GASTROJEJUNOSTOMY,,PRIOR SURGERY,OTHER,,2010-12-21,2010-12-21,BEFORE
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-19,,ONGOING
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,RHEUMATIC FEVER,Rheumatic fever,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,BEFORE
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,L EFT SIDED CEA FOR SEVERE L SIDED CAROTID DISEASE,Carotid artery disease,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010-11-11,,BEFORE
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PORCINE AORTIC VALVE REPLACEMENT SURGERY,Aortic valve replacement,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-11-11,,BEFORE
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,"SIDE TO SIDE ROUX-EN-Y HEPATICOJEJUNOSTOMY, LOOP GASTROJEJUNOSTOMY",Gastroenterostomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-12-21,,BEFORE
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,"SIDE TO SIDE ROUX-EN-Y HEPATICOJEJUNOSTOMY, LOOP GASTROJEJUNOSTOMY",Hepaticojejunostomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-12-21,,BEFORE
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,7.0,GLAUCOMA,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,5.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,4.0,CONGENITAL INGUINAL HERNIA REPAIRED,Inguinal hernia repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,6.0,PILONIDAL CYST REMOVED,Pilonidal sinus repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1980,,BEFORE
CO-101-001,CO-101-001-009-002,01009002,009,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,AORTIC VALVULE INSUFFICIENCY,Aortic valve incompetence,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-09-02,,ONGOING
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,MITRAL VALVULE INSUFFICIENCY,Mitral valve incompetence,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-09-02,,ONGOING
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ASYMPTOMATIC CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-08-24,,ONGOING
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANGIOMA OF CARDIA,Haemangioma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-09-03,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PROSTATIC ADENOCARCINOMA,Prostate cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2000,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,TRIGEMINAL NEURALGIA,Trigeminal neuralgia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1968,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEPHROLITHIASIS,Nephrolithiasis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1984,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1965,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PROSTATECTOMY,Prostatectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,RENAL SURGERY,Renal surgery,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1984,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VARICECTOMY,Varicose vein operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1984,,BEFORE
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,INFERIOR LIMBS VARIXES,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1960,,ONGOING
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ETHYLIC PANCREATITS,Alcoholic pancreatitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1975,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,GASTRIC ULCUS,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1969,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,COMMON BILE DUCT SLUDGE,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1998,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,RIGHT RIB FRACTURE,Rib fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1980,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERURICEMIA,Hyperuricaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN (PANCREATIC CANCER RELATED),Cancer pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-11-08,,ONGOING
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,EPILEPSY,Epilepsy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1998-10,,ONGOING
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1961,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1999,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,GASTRECTOMY,Gastrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1969,,BEFORE
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,INFERIOR LIMBS ARTERIOPATHY,Arterial disorder,MEDICAL HISTORY,,VASCULAR DISORDERS,1999,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,SPLENIC THROMBOSIS (CANCER RELATED),Splenic vein thrombosis,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-08,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,LEFT RETINITIS,Retinitis,MEDICAL HISTORY,,EYE DISORDERS,2000,,BEFORE
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ESOPHAGITIS,Oesophagitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-11,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,DIABETES MELLITUS TYPE II,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ABDOMINAL PAIN (CANCER RELATED),Cancer pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-11,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,VARIXES CURE,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1960,,BEFORE
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-15,,ONGOING
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-15,,ONGOING
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,INTRADUCTAL PAPILLARY MUCINOUS PANCREATIC TUMOUR,Intraductal papillary mucinous neoplasm,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2007,,ONGOING
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PROSTATIC NEOPLASIA,Neoplasm prostate,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1995,,BEFORE
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEPHROLITHIASIS,Nephrolithiasis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1973,,BEFORE
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,AORTO-CORONARY BY-PASS,Coronary artery bypass,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1993,,BEFORE
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,TOTAL RADICAL PROSTATECTOMY,Radical prostatectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995,,BEFORE
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,AORTIC ANEURYSM,Aortic aneurysm,MEDICAL HISTORY,,VASCULAR DISORDERS,1993,,BEFORE
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SUPRAVENTRICULAR TACHYCARDIA,Supraventricular tachycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,INTRAOCULAR HYPERTENSION,Ocular hypertension,MEDICAL HISTORY,,EYE DISORDERS,1993,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PENICILLINS ALLERGY,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,QUININ ALLERGY,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PALUDISM,Malaria,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,,,BEFORE
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,TENOSYNOVITIS OF HANDS,Tenosynovitis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1993,,BEFORE
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ARTERIAL PULMONARY HYPERTENSION,Pulmonary arterial hypertension,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-08-13,,ONGOING
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1988,,ONGOING
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BILIARY STENT PLACEMENT,,PRIOR SURGERY,OTHER,,2011-12-12,2011-12-12,BEFORE
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HEPATIC BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-12-27,2011-12-27,BEFORE
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PANCREATIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-24,,ONGOING
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HEARTBRUN,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INGUINAL HERNIA INTERVENTION,Inguinal hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1996,,BEFORE
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,SPLENO-PANCREATECTOMY,,PRIOR SURGERY,RESECTION,,2009-09-15,2009-09-15,BEFORE
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HEARTBURN,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,STOMATITIS,Stomatitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HEMOCHROMATOSIS,Haemochromatosis,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1930-11-19,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HYPOGLYCEMIA,Hypoglycaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-05,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ARTHROSIS,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SPLENIC VEIN THROMBOSIS,Splenic vein thrombosis,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HIATUS HERNIA,Hiatus hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008-02-26,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CHRONIC SINUSITIS,Chronic sinusitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,INTRADUCTAL PAPILLARY MUCINOUS TUMOUR OF THE PANCREAS,Intraductal papillary mucinous neoplasm,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2007-05,,ONGOING
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PHLEBITIS,Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,EXPLORATIVE LAPAROSCOPY,,PRIOR SURGERY,EXPLORATORY,,2010-12-27,2010-12-27,BEFORE
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,HYDROCELE TESTIS RIGHT,Hydrocele,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2011-01,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,MORBUS CROHN,Crohn's disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CHOLECYSTOLITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,CYST OF ACETABULUM,Bone cyst,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,SPONDYLOSIS DEFORMANS,Spinal osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,TUMOR PAIN,Tumour pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,HYPERPLASIA OF PROSTATE,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ANGIOSCLEROSIS,Angiosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HEARTBURN,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,VITAMINE B1 DEFIENCY,Vitamin B1 deficiency,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,STENT OF GALL,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-11,,ONGOING
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,3.0,HYPOTHYREOSIS,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,RETINAL DETACHMENT,Retinal detachment,MEDICAL HISTORY,,EYE DISORDERS,2008,,BEFORE
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,OBSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ARTHROSCOPY,Arthroscopy,MEDICAL HISTORY,,INVESTIGATIONS,2011-03,,BEFORE
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,LOW APETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,POSTMENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1995,,ONGOING
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CHOLEZYSTEKTOMIE,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1981,,BEFORE
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,MYOMA EXCISION,Myomectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995,,BEFORE
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,DECREASED HEARING ABILITY,Hypoacusis,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,OTITIS MEDIA WITH EFFUSION,Middle ear effusion,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,GLAUKOM,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,1993,,BEFORE
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,PAIN ABDOMEN NOS,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,OBSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-05,,BEFORE
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,FLATULENCE,Flatulence,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-13,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,OTITIS MEDIA WITH EFFUSION,Otitis media,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,GASTROSCOPY,Endoscopy upper gastrointestinal tract,MEDICAL HISTORY,,INVESTIGATIONS,2011-07-13,,BEFORE
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1980,,BEFORE
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,GASTROESOPHAGEAL REFLUX,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INTERMITTEND BACKPAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,MONOCLONAL GAMMOPATHIA,Monoclonal gammopathy,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-12,,ONGOING
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,INTERMITTEND HEADACHE,Headache,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,GLAUCOMA,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DIVERTICULOSIS,Diverticulum,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,BEFORE
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,RESECTION OF 2/3 OF THE STOMAC DUE TO ULCERA,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1973,,BEFORE
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CHOLECYSTEKTOMY DUE TO IATROGENIC INJURY OF THE GALL BLADDER,Gallbladder injury,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-06-29,,BEFORE
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN DUE TO PANCREATIC CANCER,Cancer pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-06-29,,ONGOING
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,PTCD TO ASSURE BILE DRAINAGE,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-10-07,2011-10-07,BEFORE
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ACUTE PANCREATITIS,Pancreatitis acute,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,BEFORE
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,"ELEVATED LIVER PARAMETERS (GGT, AP ALAT, ASAT)",Alanine aminotransferase increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,"ELEVATED LIVER PARAMETERS (GGT, AP ALAT, ASAT)",Aspartate aminotransferase increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,"ELEVATED LIVER PARAMETERS (GGT, AP ALAT, ASAT)",Blood alkaline phosphatase increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,"ELEVATED LIVER PARAMETERS (GGT, AP ALAT, ASAT)",Gamma-glutamyltransferase increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,MALNUTRITION AND REDUCED APETITE,Malnutrition,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1980,,ONGOING
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CHOLECYSTECTOMIE,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1975,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,CORONARY HEART DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,ICD IMPLANTATION DUE TO RHYTHMPROBLEMS DUE TO CORONAR HEART DISEASE WITH LONG QT- SYNDROME,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,ICD IMPLANTATION DUE TO RHYTHMPROBLEMS DUE TO CORONAR HEART DISEASE WITH LONG QT- SYNDROME,Long QT syndrome,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HEART ATTACK,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2011,,BEFORE
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,BILROTH I RESECTION OF THE STOMAC DUE TO ULCERA,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1988,,BEFORE
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,MILD GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,REFLUXESOPHAGITIS,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,CHOLESTASIS,Cholestasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-10-24,,BEFORE
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,HYPERURICEMIA,Hyperuricaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,VITMIN D DEFICIANCY,Vitamin D deficiency,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,MILD DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NYCTURIA,Nocturia,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-10-24,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ACUTE RENAL FAILURE,Renal failure acute,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-10,,BEFORE
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,INCREASED SWEATING AT NIGHT,Hyperhidrosis,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-24,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,ICD IMPLANTATION DUE TO RHYTHMPROBLEMS DUE TO CORONAR HEART DISEASE WITH LONG QT- SYNDROME,Implantable defibrillator insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,VARICOSE VEINS OF THE LEGS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,LOCAL EXCISION AND DESTRUCTION OF DISEASED TISSUE,,PRIOR SURGERY,OTHER,,2010-12-07,2010-12-07,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MYORCARDITIS,Myocarditis,MEDICAL HISTORY,,CARDIAC DISORDERS,1995,,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL CRAMPS,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,EPIGASTRALGIA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-09,,ONGOING
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,TRAUMATIC BRAIN INJURY,Craniocerebral injury,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2010-06,,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MALAR FRACTURE,Jaw fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1981,,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FRACTURE OF RIB,Rib fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2010-06,,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-12-07,,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,INTERVERTEBRAL DISCS PROLAPSE OPERATION,Intervertebral disc operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1975,,BEFORE
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ESOPHAGUS DIVERTICULUM OPERATION,Oesophageal operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1980,,BEFORE
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ABDOMINAL FULLNESS,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,EPIGASTRALGIA GRADE 1,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-03,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-12,,BEFORE
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,BACK PAIN GRAD 1,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,AORTIC ANORYSM OPERATION,Aortic aneurysm repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006,,BEFORE
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,"EXPLORATORY, NO RESECTION",,PRIOR SURGERY,EXPLORATORY,,2011-01-13,2011-01-13,BEFORE
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INTERMITTEND REFLUX OESOPHAGITIS,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MELLITUS TYPE II,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1976,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,MACULAR DEGENERATION,Macular degeneration,MEDICAL HISTORY,,EYE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,RETINAL DETACHMENT,Retinal detachment,MEDICAL HISTORY,,EYE DISORDERS,2010,,BEFORE
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ACID REFLUX,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HEMOGLOBIN INCREASED,Haemoglobin increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-04-28,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPERGLYCEMIA,Hyperglycaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-05-12,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,DISK PROLAPSE,Intervertebral disc protrusion,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1975,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1972,,BEFORE
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ABDOMINAL AORTIC ANEURYM,Aortic aneurysm,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,EXPLORATORY LAPAROTOMY,,PRIOR SURGERY,EXPLORATORY,,2011-07-04,2011-07-04,BEFORE
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2009,,ONGOING
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PAIN ABDOMINAL,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,BEFORE
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,POLYP OF THE COLON,Colonic polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,BEFORE
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,BLOOD STOOL,Haematochezia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,BEFORE
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-08,,BEFORE
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INAPPETENCE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,APPENDECTOTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NOSE SURGERY - TYPE UNKNOWN,Nasal operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,"ERCP, ENDOSCOPIC SPHINCTEROTOMY, ENDOBILARY STENT PLACEMENT",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-11-04,2010-11-04,BEFORE
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PANCREATIC EXOCRINE INSUFFICENCY,Pancreatic insufficiency,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,5.0,PYLORUS PRESERVING PANCREATIC DUODENECTOMY,,PRIOR SURGERY,RESECTION,,2009-09-02,2009-09-02,BEFORE
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,4.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-07,,ONGOING
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,3.0,PERIPHERAL NEUROPATHY,Neuropathy peripheral,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,OSTEOMYELITIS,Osteomyelitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2003,,BEFORE
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,SUBARACHNOID HAEMORRHAGE,Subarachnoid haemorrhage,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2002,,BEFORE
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1991,,BEFORE
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,METAL STENT INSERTED,,PRIOR SURGERY,OTHER,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,GASTRO ESOPHAGEAL REFLUX DISORDER,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,INSULIN DEPENDENT DIABETES,Type 1 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1991,,ONGOING
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1979,,BEFORE
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,GASTRO ESOPHAGEAL REFLUX DISORDER,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,SHINGLES,Herpes zoster,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010-09,,BEFORE
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,NON INSULIN DEPENDANT DIABETES MELITUS,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,3.0,GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1985,,ONGOING
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,5.0,TUMOUR PAIN,Tumour pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-10,,ONGOING
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1989,,ONGOING
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,UPPER ABDOMINAL PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1980,,ONGOING
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA INTERMITTENT,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,SECRETORY PANCREATIC INSUFFICIENCY,Pancreatic insufficiency,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10-14,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-02,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,PAROXYSMAL ATRIAL FIBRILLATION,Atrial fibrillation,MEDICAL HISTORY,,CARDIAC DISORDERS,2008-11,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,MENIERES DISEASE,Meniere's disease,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,2009-08,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,UPPER ABDOMINAL PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,INTERMITTENT VOMITTING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-15,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,RHINITIS,Rhinitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1996,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-12,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,LOSS OF APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-02,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CONTACT DERMATITIS,Dermatitis contact,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,DRY SKIN,Dry skin,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,NIGHT SWEATS,Night sweats,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-02,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005-10,,ONGOING
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ORTHOSTATIC HYPOTENSION,Orthostatic hypotension,MEDICAL HISTORY,,VASCULAR DISORDERS,2012-02-27,,ONGOING
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,3.0,PROSTATE CANCER,Prostate cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2007-07-19,,BEFORE
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,8.0,URINARY INCONTINENCE,Urinary incontinence,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,4.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2007-12-01,,BEFORE
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,5.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-12,,BEFORE
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,9.0,HYPERHIDROSIS,Hyperhidrosis,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,7.0,BLEEDING,Haemorrhage,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-10,,BEFORE
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,6.0,THROMBOPHLEBITIS,Thrombophlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-10-24,,BEFORE
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,SUPERCLAVICULAR PAIN,Pain,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-26,,ONGOING
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HIPOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPOTIRDOIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,SMOKING,Tobacco user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,BEFORE
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DIABETES TYPE II,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,BRONCHIAL ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1980,,ONGOING
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1993,,BEFORE
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANTIPLATELET THERAPY,Antiplatelet therapy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2004,,ONGOING
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,COLEDOCODUODENO ANASTOMOSIS,,PRIOR SURGERY,EXPLORATORY,,2011-11-11,2011-11-11,BEFORE
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TOBACCO USE,Tobacco user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,BEFORE
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CESAREAN,Caesarean section,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2001,,BEFORE
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEAS,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-04,,ONGOING
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,LOMBAR PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-04,,BEFORE
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHRONIC ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,COLESTASIS,Cholestasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-09,,BEFORE
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,URINARY INFECTION,Urinary tract infection,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2011-09-20,,BEFORE
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-08,,BEFORE
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ASCITIS,Ascites,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-07,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-11,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,EDEMA ON LOWER LIMBS,Oedema peripheral,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ARTHROSIS ON COLUMN,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ARTHROSIS ON LOWER LIMBS,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,SPONDILO ARTHROSIS ON THORACIC SPINE,Spinal osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-07,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-08-11,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,COLONIC DIVERTICULOSIS,Diverticulum intestinal,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ASPIRIN ALERGY,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYPERURICEMIA,Hyperuricaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DIABETES MELLITUS TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NEPHROLITHIASIS,Nephrolithiasis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1973,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL AORTIC ANEURISM,Aortic aneurysm,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,BIOPSY OF LIVER METS,,PRIOR SURGERY,EXPLORATORY,,2010-11-16,2010-11-16,BEFORE
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY AND STENT INSERTION,,PRIOR SURGERY,OTHER,,2010-10-04,2010-10-04,BEFORE
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANAEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-09,,ONGOING
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,LUMBOSACRAL DISC DISEASE,Intervertebral disc disorder,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,RIGHT FOOT DROP,Peroneal nerve palsy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ULTRASOUND GUIDED BIOPSY OF LIVER METASTASIS,,PRIOR SURGERY,EXPLORATORY,,2011-06-06,2011-06-06,BEFORE
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,BEFORE
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,LOSS OF APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,RIGHT SHOULDER PAIN,Musculoskeletal pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PLANTAR FASCIITIS,Plantar fasciitis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05,,BEFORE
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,REMOVAL OF SEBACEOUS CYSTS,Sebaceous cyst excision,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1981,,BEFORE
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,VASECTOMY,Vasectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1990,,BEFORE
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,LIVER BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-07-29,2011-07-29,BEFORE
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,DRY MOUTH,Dry mouth,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,BEFORE
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ALLERGY TO PENICILLIN,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,LEFT SIDED RIB CAGE PAIN,Musculoskeletal chest pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07,,BEFORE
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,OSTEOARTHRITIS,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,MULTIPLE PULMONARY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08,,ONGOING
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,PSORIASIS,Psoriasis,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ERCP AND STENT INSERTION,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-10-10,2011-10-10,BEFORE
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,STAGING LAPAROSCOPY AND BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-11-09,2011-11-09,BEFORE
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,INDIGESTION,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,FLATULENCE,Flatulence,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,LEG CRAMPS,Muscle spasms,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,TRANSIENT ISCHEMIC ATTACK,Transient ischaemic attack,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,DIAGNOSTIC BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-02-25,2011-02-25,BEFORE
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,RETINITIS PIGMENTOSA,Retinitis pigmentosa,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",1987,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,LOWER ABDOMINAL PAIN,Abdominal pain lower,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-03,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,ERRATIC CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-03,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,DIARRHOEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,GASTRIC REFLUX,Reflux gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-02,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,MENOPAUSAL,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,ONGOING
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,LAMINECTOMY,Spinal laminectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1991,,BEFORE
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,MULTIPLE LIVER BIOPSIES,,PRIOR SURGERY,EXPLORATORY,,2011-04-04,2011-04-04,BEFORE
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,RUQ PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,BEFORE
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,STEATORRHOEA,Steatorrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GALLSTONES,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-04-18,,ONGOING
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PILONIDAL SINUS,Pilonidal cyst,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1989,,BEFORE
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-01,,ONGOING
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,BILATERAL HIP PAIN,Arthralgia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ECTOPIC PREGNANCY,Ectopic pregnancy,MEDICAL HISTORY,,"PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS",1995,,BEFORE
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,BEFORE
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,TONSILLECTOMY,Tonsillectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1991,,BEFORE
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,OMENTAL BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-04-08,2011-04-08,BEFORE
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MENIERE'S DISEASE,Meniere's disease,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CENTRAL ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,BARRETTS OESOPHAGUS,Barrett's oesophagus,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,MALABSORPTION,Malabsorption,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-20,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-03,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPERCHOLESTEROLAEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIABETES TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,SCATTERED WHEEZE,Wheezing,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",,,BEFORE
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,TELANGIECTASIA,Telangiectasia,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,,,BEFORE
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-06,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HIATUS HERNIA,Hiatus hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1980,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09-21,,ONGOING
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,BEFORE
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-11,,BEFORE
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ACIDITY,Hyperchlorhydria,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BILIARY TRACT OBSTRUCTIONS,Bile duct obstruction,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,,,BEFORE
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,DIARRHOEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-24,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-14,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-04,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LETHARGY,Lethargy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-12-14,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-12-14,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,CHRONIC AIRWAY DISEASE,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-10,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,PULMONARY ARTERY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011,,ONGOING
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DEEP VEIN THROMBOSIS IN LEFT LEG,Deep vein thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANGINA (SPECIFIC TYPE UNKNOWN),Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,GENERALISED DISEASE RELATED PAIN,Pain,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ERCP,Endoscopic retrograde cholangiopancreatography,MEDICAL HISTORY,,INVESTIGATIONS,2011-12-09,,BEFORE
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ARTHRITIS,Arthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,BEFORE
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,BILIARY STENT INSERTION,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-12-09,,BEFORE
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,APENDICECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,TONSILECTOMY,Tonsillectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ARTHROSCOPY,Arthroscopy,MEDICAL HISTORY,,INVESTIGATIONS,2006-03,,BEFORE
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007-02-01,,ONGOING
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DERMATITIS,Dermatitis,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ENDOMETRIAL ABLATION,Endometrial ablation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2007-03,,BEFORE
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1997-01-01,,ONGOING
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NOTHING REMOVED WHEN LIVER LESIONS OBSERVED,,PRIOR SURGERY,RESECTION,,2010-12-10,2010-12-10,BEFORE
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-06,,ONGOING
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GENERAL JOINT AND MUSCLE PAIN,Arthralgia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GENERAL JOINT AND MUSCLE PAIN,Myalgia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,DIARRHOEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-11,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,GORD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,BILATERAL LEG OEDEMA,Oedema peripheral,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-22,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,JAUNDICE,Jaundice,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-02,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,NEEDLE BIOPSY LIVER,Biopsy liver,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,GASTROSCOPY,Endoscopy upper gastrointestinal tract,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,GASTROSCOPY,Endoscopy upper gastrointestinal tract,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ABDOMINAL EXAM OF PANCREASE UNDER ULTRASOUND,Ultrasound abdomen,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,LOW BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,POST MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2010-01,,ONGOING
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,VENTRAL HERNIA REPAIR,Abdominal hernia repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2002,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1975,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,BILE DUCT PLASTIC STENT PLACEMENT,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-02,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,LAPROSCOPIC CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1982,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,LAPROSCOPIC CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,RIGHT KNEE ARTHROPLASTY,Knee arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1987,,BEFORE
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,TONSILLECTOMY,Tonsillectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1979,,BEFORE
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,BILI-DIGESTIVE DERIVATION,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-08-05,2011-08-05,BEFORE
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ASCITIS,Ascites,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-20,,ONGOING
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,JAUNDICE,Jaundice,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-07-15,,ONGOING
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,LEFT BUNDLE BRANCH BLOCK,Bundle branch block left,MEDICAL HISTORY,,CARDIAC DISORDERS,,,BEFORE
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-29,,BEFORE
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ALCOHOLISM,Alcoholism,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1971,,BEFORE
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,SMOKING,Tobacco user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1981,,BEFORE
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,BILIARY DRAINAGE,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-03-05,2011-03-05,BEFORE
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,HEPATIC BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-06-30,2011-06-30,BEFORE
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-21,,ONGOING
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ALLERGY TO SEAFOOD,Food allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1955,,ONGOING
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1995,,ONGOING
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,INSERTION KEHR DRAIN,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-03-05,,ONGOING
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,BILIARY DRAIN,Biliary drainage,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-02-28,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,FILARIASIS,Filariasis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,BILHARZIASIS,Schistosomiasis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ASYMPTOMATIC PORTERAGE OF ANTIGEN HBS,Hepatitis B surface antibody positive,MEDICAL HISTORY,,INVESTIGATIONS,1973-03-25,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12-30,,ONGOING
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12-30,,ONGOING
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PNEUMOPATHY,Lung disorder,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1985,,BEFORE
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,VARICAL STRIPPING,Varicose vein operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,OPEN GLAUCOMIA,Open angle glaucoma,MEDICAL HISTORY,,EYE DISORDERS,2004,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-15,,ONGOING
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,TENNIS ELBOW,Epicondylitis,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1997-05,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,LEFT BARTHOLINITIS,Bartholinitis,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,RIGHT BARTHOLINITIS,Bartholinitis,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,1975,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,OVARIAN CYST,Ovarian cyst,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,1991-04,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1958,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,CERVICAL CONIZATION,Cervical conisation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-07,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2005-04,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-01-03,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,RADIOIODINE ON THYROID,Radioactive iodine therapy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995-06,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,RADIOIODINE ON THYROID,Radioactive iodine therapy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2002,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,THYROIDECTOMIA,Thyroidectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1977-01,,BEFORE
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,TONSILLECTOMY,Tonsillectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1950,,BEFORE
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,"HEPATICO-JEJUNALE, GASTRO-JEJUNOSTOMIE, DUODENO-JEJUNALE",,PRIOR SURGERY,OTHER,,2010-12-29,2010-12-29,BEFORE
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HIGH BLOOD PRESSURE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1999,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,MACULAR DEGENERATION,Macular degeneration,MEDICAL HISTORY,,EYE DISORDERS,2009-02,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-03,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-03,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-03,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,COUGH,Cough,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04,,ONGOING
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ASYMPTOMATIC PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-17,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,PAIN ABDOMEN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,COLON POLYPS,Colonic polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-15,,BEFORE
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,OBSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ACHILLES TENDON RUPTURE,Tendon rupture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1986,,BEFORE
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,BEFORE
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PAIN BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,BENIGN TUMOR THORAX LEFT,Benign neoplasm,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1983,,BEFORE
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,RENAL CYSTES,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,BENIGN PROSTATAHYPERPLASIA,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NIGHT SWEET,Night sweats,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ARTERIAL HYPERTONIA,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DUODENALSTENOSIS,Duodenal stenosis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,REFLUXESOPHAGITIS,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PARADONTITIS,Periodontitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,KIDNES CYSTIS,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,BILIODIGESTIVE ANASTOMOSIS,Biliary anastomosis,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-04-19,,ONGOING
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CHOLECYSTECTOMIA,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-04-19,,BEFORE
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-28,,BEFORE
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CHOLANGITIS,Cholangitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABVETES MELL. II,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,OSTEOPOROSE,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,POSTMENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,ONGOING
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ARTERIELLE HYPERTONIE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1981,,ONGOING
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CHRON. PANKCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTONIA,Hypertonia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,BILODIGESTIVE ANASTOMOSE,Biliary anastomosis,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1991,,ONGOING
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ABSOLUT ARRHYTMIA,Atrial fibrillation,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-04-26,,ONGOING
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,LIVER TRANSPLANT BECAUSE OF HEPATHORENAL SYNDROME WITH HEPATIC CIRRHOSIS BECAUSE OF ALCOHOL ABUSE,Hepatic cirrhosis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2002-10,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LIVER TRANSPLANT BECAUSE OF HEPATHORENAL SYNDROME WITH HEPATIC CIRRHOSIS BECAUSE OF ALCOHOL ABUSE,Hepatorenal syndrome,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2002-10,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ATTAC K OF GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-04-30,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,SWELLING OF THE CUBITAL JOINT,Joint swelling,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-26,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LIVER TRANSPLANT BECAUSE OF HEPATHORENAL SYNDROME WITH HEPATIC CIRRHOSIS BECAUSE OF ALCOHOL ABUSE,Alcohol abuse,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2002-10,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DEEP VENE THROMBOSIS,Deep vein thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-04-18,,BEFORE
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ARTIRIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1991,,BEFORE
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,EXPLORATIVE LAPAROTOMIE,,PRIOR SURGERY,EXPLORATORY,,2011-08-16,2011-08-16,BEFORE
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,GLAUCOM BOTH SIDES,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,REFLUXOESOPHAGITIS,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HELIOBACTERPYLORI ASSOZIIERTE PANGASTRITIS,Helicobacter gastritis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,,,BEFORE
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPERLIPIDMIE,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ARTERIELLE HYPERTONIE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CARDIAC DYSRHYTHMIA,Arrhythmia,MEDICAL HISTORY,,CARDIAC DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PYROSIS,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PANCREATIC INSUFFICIENCY,Pancreatic insufficiency,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,COPD,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1993,,ONGOING
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,STENT IN DUCTUS HEPATOCHOLEDUCTUS,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-10-15,,ONGOING
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,OBSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DIABETES MELLITUS TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,PAIN (TUMOUR),Tumour pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-11,,ONGOING
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,SLEEP DISTURBANCE,Sleep disorder,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,"PANCREATIC TAIL RESECTION, SPLENECTOMY, HEMICOLEKTOMY",,PRIOR SURGERY,RESECTION,,2010-12-21,2010-12-21,BEFORE
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPERTHYROIDISM,Hyperthyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,"PAIN (BACK, ABDOMEN)",Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,CONTRAST DYE ALLERGY,Contrast media allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2011-02-01,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,PLATELET COUNT INCREASED,Platelet count increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-01,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,"PAIN (BACK, ABDOMEN)",Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,DISC PROLAPS,Intervertebral disc protrusion,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,POSTMENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2010-10,,ONGOING
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1987,,BEFORE
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,HEMICOLECTOMY,Colectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-12-21,,BEFORE
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,SPLENECTOMY,Splenectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-12-21,,BEFORE
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,BILIODIGESTIVE ANASTOMOSIS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-02-04,2011-02-04,BEFORE
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,RESECTION OF LIVER METASTASIS,,PRIOR SURGERY,RESECTION,,2011-02-04,2011-02-04,BEFORE
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPOCALCEMIA,Hypocalcaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-02-06,,ONGOING
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN (BACK),Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,R0-RESECTION,,PRIOR SURGERY,RESECTION,,2008-06-30,2008-06-30,BEFORE
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SLEEP DISTURBANCE,Sleep disorder,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,POSTMENOPAUSAL STATUS,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-06-30,,BEFORE
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,SIGMA POLYP EXCISION,Colonic polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-30,,BEFORE
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,TUMOR PAIN,Tumour pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10,,ONGOING
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,SLEEP DISTURBANCES,Sleep disorder,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYSTERECTOMIA,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1993,,ONGOING
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,VARICOSE VEINS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1985,,ONGOING
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PAIN ABDOMEN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,OBSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,VASECTOMY,Vasectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1996,,BEFORE
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,R0 RESECTION,,PRIOR SURGERY,RESECTION,,2009-01-30,2009-01-30,BEFORE
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PANCREATIC INSUFFICIENCY,Pancreatic insufficiency,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009-01,,ONGOING
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,POSTMENOPAUSE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1993,,ONGOING
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHOLEZYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2009-01-30,,BEFORE
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CORONARY THROMBOSIS,Coronary artery thrombosis,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,BEFORE
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,HYPOTHYREOSIS,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PAIN UPPER ABDOMEN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ARTHROSIS RIGHT SHOULDER,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ARTHROSIS THUMB LEFT,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,APOPLEXIA,Cerebrovascular accident,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TENSION FREE VAGINAL TAPE SURGERY FOR REMOVAL OF INCONTINENCE,Incontinence,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,HIP ENDOPROTHESIS IN THE BODY LEFT SIDE,Joint prosthesis user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1999,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,HIP ENDOPROTHESIS IN THE BODY RIGHT SIDE,Joint prosthesis user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2002,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,POSTMENOPAUSE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1985,,ONGOING
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,BYPASS OPERATION,Vascular graft,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2007,,BEFORE
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,14.0,HYPOTHYREOSIS,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,11.0,GLAUCOMA,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,7.0,UMBILICUAL HERNIA,Umbilical hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1953,,BEFORE
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,9.0,GALLSTONE,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1998,,BEFORE
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,6.0,FRACTURE OF THORACAL VERTEBRAL BODY 4 WITH COMPRESSION OF SPINAL CHANNEL,Thoracic vertebral fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-02-07,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,10.0,DIABETES MELLITUS TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,4.0,PAIN BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,5.0,FRACTURE OF THORACAL VERTEBRAL BODY 4 WITH COMPRESSION OF SPINAL CHANNEL,Spinal cord compression,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2012-02-07,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,13.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1993,,ONGOING
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,3.0,APENDECTOMIE,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1961,,BEFORE
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,8.0,BREAST REDUCTION,Mammoplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1999,,BEFORE
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,12.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ATRIAL FIBRILLATION,Atrial fibrillation,MEDICAL HISTORY,,CARDIAC DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,THALASSEMIA MINOR,Thalassaemia beta,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",1980,,BEFORE
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,COLONIC ADENOMA/RIGHT EMICOLECTOMY,Colon adenoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1997,,BEFORE
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,URINARY CALCULI,Calculus urinary,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1998,,BEFORE
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CHRONIC OBSTRUCTIVE LUNG DISEASE,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2009,,BEFORE
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07,,ONGOING
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-08,,ONGOING
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01-30,,ONGOING
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-07,,ONGOING
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,PAIN IN LEGS,Pain in extremity,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-02-02,,ONGOING
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ENDOMETRIOSIS,Endometriosis,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,1990,,BEFORE
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,THROMBOEMBOLISM,Embolism,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-01-21,,BEFORE
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,COLIC CANCER,Colon cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1995-12,,BEFORE
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HIGH BLOOD PRESSURE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,AMI,Acute myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,BEFORE
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-18,,BEFORE
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,SAFENECTOMY LEFT LEG,Phlebectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-11,,BEFORE
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,AORTIC ANEURISM WITH PARIETAL THROMBOSIS,Aortic aneurysm,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-03-18,,ONGOING
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,AORTIC ANEURISM WITH PARIETAL THROMBOSIS,Arterial thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-03-18,,ONGOING
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOPHLEBITIS LEFT LEG,Thrombophlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-11,,BEFORE
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,THROMBOPHLEBITIS RIGHT ARM,Thrombophlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-02,,BEFORE
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THOMBOSIS OF SPLENIC VEIN,Splenic vein thrombosis,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-07,,ONGOING
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GLAUCOMA,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,TAVANIC,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PROSTATIC ADENOMECTOMY,Prostatectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2004-11-23,,BEFORE
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,THYROIDECTOMY,Thyroidectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2005,,BEFORE
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SPLENIC VEIN THROMBOSIS,Splenic vein thrombosis,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-17,,ONGOING
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008,,BEFORE
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,URINARY TRACT INFECTION,Urinary tract infection,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2005,,BEFORE
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANXIETY/DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2006,,ONGOING
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,AORTIC VALVE REPLACEMENT,Aortic valve replacement,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006,,BEFORE
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTHENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HERPES ZOSTER,Herpes zoster,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010-10,,ONGOING
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,GLUCOSE INTOLLERANCE,Glucose tolerance impaired,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,BASOCELLULAR CARCINOMA,Basal cell carcinoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010,,ONGOING
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,RIGHT CAROTID PLAQUE REMOVAL,Carotid arteriosclerosis,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010-06,,BEFORE
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,AORTIC ANEURISMECTOMY,Aortic aneurysm repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2003-01,,BEFORE
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,COLECISTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1982-04,,BEFORE
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERCOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,BENIGN PROSTATIC HYPERTROPHY,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,1999,,ONGOING
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-01,,BEFORE
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HEPATITIS C VIRUS,Hepatitis C,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2009,,ONGOING
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,APPENDICECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,EMORROIDECTOMY,Haemorrhoid operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LAPAROSCOPIC BILATERAL HISTERO-ANNESSIECTOMY,Hysterosalpingo-oophorectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1985,,BEFORE
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,REMOVAL OF THYROGLOSSAL DUCT,Thyroid operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,BEFORE
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08,,ONGOING
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,WIGHT DECREASED,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-08,,ONGOING
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,BILATERAL ATHEROMASIA CAROTID,Carotid arteriosclerosis,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,OCCLUSION OF ANTERIOR AND POSTERIOR TIBIAL ARTHERY,Peripheral arterial occlusive disease,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HEMORRAGIC SHOCK,Shock haemorrhagic,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-09-06,,BEFORE
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DUODENOCEFALOPANCREASECTOMY,,PRIOR SURGERY,RESECTION,,2011-08-11,2011-08-11,BEFORE
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,SURGERY: NODULECTOMY OF BENING NODULE,Mass excision,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,SURGERY: POLYPECTOMY OF VOCAL CORDS,Vocal cord polypectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1968,,BEFORE
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,BIOPSY,,PRIOR SURGERY,OTHER,,2012-02-03,2012-02-03,BEFORE
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DEPRESSIVE SYNDORME,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,,,ONGOING
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1987,,ONGOING
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,LIVER BIOPSY,,PRIOR SURGERY,OTHER,,2012-02-23,2012-02-23,BEFORE
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-01,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-02-01,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,HYPERCHOLESTEREMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPOMAGNESEMIA,Hypomagnesaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009-07,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1985,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ALOPECIA,Alopecia,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,BEFORE
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1978,,ONGOING
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANAEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-15,,ONGOING
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,MILD HEPATOMEGALY,Hepatomegaly,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-08-15,,ONGOING
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,H. PYLORI INFECTION,Helicobacter infection,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2011-06-04,,BEFORE
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,URINARY TRACT INFECTION,Urinary tract infection,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2011-06-25,,BEFORE
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CRAMPING IN HANDS AND FEET,Muscle spasms,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,SILASTIC CATHETER PLACEMENT TO RELIEVE URINARY RETENTION,Urinary retention,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-06-25,,BEFORE
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PROSTATIC HYPERTROPHY,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010-12,,BEFORE
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HIP REPLACEMENT,Hip arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2003,,BEFORE
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PALPABLE MASS IN EPIGASTRIC REGION,Abdominal mass,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-03,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-13,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10-13,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERCHOLESTEREMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DYSPNOEA,Dyspnoea,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-03,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PULMONARY EMBOLUS,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-14,,BEFORE
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ALOPECIA,Alopecia,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-03,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DUODENAL STENT,Intestinal stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-10-21,,ONGOING
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,LEFT-SIDED DVT,Deep vein thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-06,,BEFORE
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,LOWER ABDOMINAL PAIN,Abdominal pain lower,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-12,,ONGOING
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09-12,,ONGOING
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,HYPERCHOLESTEREMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1989,,ONGOING
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,BILIARY WALL STENT,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-09-12,,ONGOING
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1993,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,MULTIPLE GALLSTONES,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PAIN FROM GALLSTONES,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,BACK PAIN FROM MULTIPLE DISC PROLAPSE,Intervertebral disc protrusion,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ANXIETY AND DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1995,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PULMONARY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-05,,BEFORE
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,OBSTRUCTIVE SLEEP APNOEA,Sleep apnoea syndrome,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2008,,ONGOING
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,TONSILLECTOMY,Tonsillectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-05,,BEFORE
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-06,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,HYPERCHOLESTEREMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PULMONARY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-23,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1982,,BEFORE
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,TONSILLECTEMY,Tonsillectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1953,,BEFORE
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,RIGHT LEG DVT,Deep vein thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-11-22,,ONGOING
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-09,,ONGOING
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-09,,ONGOING
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-01-24,,ONGOING
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,PULMONARY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-23,,ONGOING
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,WHIPPLES,,PRIOR SURGERY,RESECTION,,2009-08-19,2009-08-19,BEFORE
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-20,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-06,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERCHOLESTEREMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HYPOMAGNESEMIA,Hypomagnesaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPONATREMIA,Hyponatraemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HEARING LOSS,Deafness,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,1999,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-13,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-20,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-20,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,APPENDICITIS,Appendicitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,,,BEFORE
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHESTY COLD,Lower respiratory tract infection,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2012-02-13,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-02-20,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PLANTAR FASCITIS OF LEFT FOOT,Plantar fasciitis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-02-13,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DYSPNOEA,Dyspnoea,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-13,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PULMONARY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-03,,ONGOING
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,SUBCUTANEOUS UMBULICAL NODULE,Subcutaneous nodule,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-01-18,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-19,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-19,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,SEASONAL ALLERGY,Seasonal allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,URINARY FREQUENCY,Pollakiuria,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CATARACT REMOVAL,Cataract operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2007-03-29,,BEFORE
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-04,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-04,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,GASTRIC VARICES,Gastric varices,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,BEFORE
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,GENERALIZED FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,LOWER EXTREMITY EDEMA,Oedema peripheral,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,PLEURAL EFFUSION,Pleural effusion,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-15,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,SLEEP APNEA,Sleep apnoea syndrome,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010,,ONGOING
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-04-10,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ADENOCARCINOMA,,PRIOR SURGERY,OTHER,,2010-08-11,2010-08-11,BEFORE
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,EXCISION SUPRAUMBILICAL LYMPH NODE,,PRIOR SURGERY,EXPLORATORY,,2010-08-31,2010-08-31,BEFORE
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,GASTROESOPHAGEAL REFLUX DISEASE,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-08-13,,BEFORE
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,SEASONAL ALLERGIES,Seasonal allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1950,,BEFORE
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ESOPHAGOGASTRODUODENOSCOPY,Oesophagogastroduodenoscopy,MEDICAL HISTORY,,INVESTIGATIONS,2010-08-11,,BEFORE
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,HYPERLIPEDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,OSTEOPENIA,Osteopenia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1962,,BEFORE
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,COPD,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1962,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,POST MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1990,,ONGOING
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-08-31,,BEFORE
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,INTERMITTENT DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERGLYCEMIA,Hyperglycaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-10-27,,ONGOING
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HERNIATED DISK,Intervertebral disc protrusion,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SQUAMOUS CELL CARCINOMA,Squamous cell carcinoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",,,BEFORE
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,POST MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1992,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1992,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,INTOLERANT TO ALL STATINS DRUGS,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1989,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DIABETES TYPE II,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1958,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DEGENERATIVE JOINT DISEASE,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1997,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,RIGHT PANTAR FASCITIS,Plantar fasciitis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2003,,BEFORE
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000,,BEFORE
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1980,,ONGOING
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011,,BEFORE
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NIACIN,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CRAWFISH,Food allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,IODINE,Iodine allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CS ELEVATED LDH,Blood lactate dehydrogenase increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-05,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERCHOLESTEREMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,OBESITY,Obesity,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011,,BEFORE
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SLEEP APNEA,Sleep apnoea syndrome,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1995,,ONGOING
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GASTRIC BYPASS,Gastric bypass,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995,,BEFORE
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GERD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BILARY OBSTRUCTION  FOM PANCRATIC CANCER MASS,Bile duct obstruction,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-07-21,,BEFORE
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES II,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,BILARY OBSTRUCTION  FOM PANCRATIC CANCER MASS,Pancreatic carcinoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-21,,BEFORE
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HTN,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-065-002,01065002,065,59.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ENDOPROSTHESIS OF HEPATOCHOLEDOCH,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-04-26,2011-04-26,BEFORE
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2005,,ONGOING
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANASTAMOSIS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-09-29,2011-09-29,BEFORE
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,MEDICAL HISTORY,,INVESTIGATIONS,2011-11-08,,BEFORE
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ADENOCARCINOMA,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-11-13,2010-11-13,BEFORE
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,EPIGASTRIAL PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10-04,,ONGOING
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-10-15,,ONGOING
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CYSTIS OF RIGHT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-10-15,,ONGOING
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1986,,ONGOING
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-10-19,,ONGOING
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ADENOCARCINOMA,,PRIOR SURGERY,RESECTION,,2010-02-09,2010-02-09,BEFORE
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ISCHEMIC HEART DISEASE:ATHEROSCLEROSIS,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-03-05,,ONGOING
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009-11-06,,ONGOING
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PAIN IN THE RIGHTSIDE OF RIBS,Musculoskeletal chest pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1967,,BEFORE
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ISCHEMIC HEART DISEASE:ATHEROSCLEROSIS,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-03-05,,ONGOING
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TACHYCARDIA,Tachycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN IN THE RIGHT SIDE OF ABDOMEN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FATIQUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DYSPNEA,Dyspnoea,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-01,,ONGOING
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,"LAPAROTOMY, LIVER BIOPSY",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-08-05,2011-08-05,BEFORE
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PAIN IN THE LEFT SITE OF ABDOMEN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-23,,ONGOING
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2003,,ONGOING
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ARTHERIAL HYPERTENSIVE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2012-01-26,,ONGOING
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PAIN IN THE EPIGASTRIC AREA AND THE RIGHT SIDE UNDER RIBS,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-17,,ONGOING
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PAIN IN THE EPIGASTRIC AREA AND THE RIGHT SIDE UNDER RIBS,Musculoskeletal chest pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009-12,,ONGOING
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VARICOSE VINE DISEASE OF THE BOTH LEG,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,2012-01-26,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,"TRUNCOCAUDAL RESECTIONOF THE PANCREAS, RESECTION OF LIVER MTS",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-12-15,2011-12-15,BEFORE
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ISCHEMIC HEART DISEASE: STABLE EXERTIONAL ANGINA,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ISCHEMIC HEART DISEASE: CONSTANT ATRIAL FIBRILATION,Atrial fibrillation,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ISCHEMIC HEART DISEASE: CONSTANT ATRIAL FIBRILATION,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ISCHEMIC HEART DISEASE: STABLE EXERTIONAL ANGINA,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FATIQUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-15,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DYSPNOE,Dyspnoea,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2009,,ONGOING
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"CHOLECYSTECTOMY, CHOLEDOCHOEUNOANASTOMOSIS",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-08-22,2011-08-22,BEFORE
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,"PERITONEAL MTS, MTS IN LIVER",,PRIOR SURGERY,EXPLORATORY,,2012-01-24,2012-01-24,BEFORE
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,OPTIC ATROPHY BOTH SIDES,Optic atrophy,MEDICAL HISTORY,,EYE DISORDERS,1961,,ONGOING
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,FATIQUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01,,ONGOING
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009-02-19,,ONGOING
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009-02-26,,ONGOING
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PAIN IN THE RIGHT SIDE UNDER THE RIBS,Musculoskeletal chest pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,COXARTHROSIS OF THE LEFT SIDE,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-09-27,,ONGOING
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ATHEROSCLEROSIS OF THE FEMORAL AND TIBIAL ARTERY,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-11-18,,ONGOING
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,EXPLORATORY LAPARATOMY,,PRIOR SURGERY,RESECTION,,2010-08-23,2010-08-23,BEFORE
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,DUADENAL ULCER,Duodenal ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-17,,ONGOING
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,DECOMPENSATED STOMACH STENOSIS,Gastric stenosis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-17,,ONGOING
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,BODY WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,LIVER BIOPSY,,PRIOR SURGERY,OTHER,,2010-10-29,2010-10-29,BEFORE
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ALLERGY FOR CONTRAST AGENTS,Contrast media allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2010-10-26,,ONGOING
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,RAPID PULSE WHEN NERVOUS,Heart rate increased,MEDICAL HISTORY,,INVESTIGATIONS,1992,,ONGOING
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,BODY WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,GASTROANASTOMOSIS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-10-13,2010-10-13,BEFORE
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,MYOCARDIODYSTROPHY,Cardiomyopathy,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-10-12,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09-06,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,CHOLECYSTITIS,Cholecystitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-09-07,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CALCINATE IN RIGHT LIVER LOBE,Hepatic calcification,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-09-07,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,FAT HEPATOSIS,Hepatic steatosis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-09-07,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BODY WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-09,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DIABETUS MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008-08,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2004,,ONGOING
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-10-12,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NO,,PRIOR SURGERY,OTHER,,2010-11-13,2010-11-13,BEFORE
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MYOCARDIODYSTROPHY,Cardiomyopathy,MEDICAL HISTORY,,CARDIAC DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC ATROPHIC GASTRITIS,Gastritis atrophic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-10,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2007,,ONGOING
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HEPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,NO,,PRIOR SURGERY,OTHER,,2010-11-17,2010-11-17,BEFORE
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,CHRONIC CARDIAC DECOMPENSATION,Cardiac failure chronic,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CATARRHAL DUODENITIS,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ULCERATIVE DISEASE OF THE STOMACH ST.REMISSION,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,RECTOSIGMOIDITIS,Proctocolitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHRONIC PYELONEPHRITIS,Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2006,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,UROLITHIASIS,Calculus urinary,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,LIVER,,PRIOR SURGERY,OTHER,,2010-11-24,2010-11-24,BEFORE
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CHRONIC HEART DISFUNCTION,Cardiac failure chronic,MEDICAL HISTORY,,CARDIAC DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,MYOCARDIODYSTROPHY,Cardiomyopathy,MEDICAL HISTORY,,CARDIAC DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DUODENOGASTRAL REFLUX,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-03,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SUPERFITIAL GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,VARICOSE DILATATION OF ESOPHAGEAL VEINS,Varices oesophageal,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-03,,ONGOING
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,LIVER BIOPSY,,PRIOR SURGERY,OTHER,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,PAIN IN LEFT SUBCOSTAL AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-25,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-19,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-10,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,BODY WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-10,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,LIVER HEMANGIOMA,Haemangioma of liver,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-11-22,,ONGOING
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CYST OF LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-11-22,,ONGOING
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DIAGNOSTIC,,PRIOR SURGERY,OTHER,,2011-01-12,2011-01-12,BEFORE
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12,,BEFORE
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-02-03,,ONGOING
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PAIN IN SUBCOSTAL AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01,,ONGOING
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-01-03,,ONGOING
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOPHLEBITIS,Thrombophlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-01-03,,BEFORE
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,BILATERAL CROSSECTOMY(THROMBOPHLEBITIS SAPHENOUS VEIN),Thrombophlebitis superficial,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-01-03,,BEFORE
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ANASTAMOSIS,,PRIOR SURGERY,RESECTION,,2010-09-02,2010-09-02,BEFORE
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,STENOCARDIA EXERTION,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-09-01,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-06-16,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,EROSIVE ESOPHAGITIS,Erosive oesophagitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10-22,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,INSUFFICIENCY CARDIAC APERTURE STOMACH,Gastrointestinal disorder,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-06-16,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CYST LIVER,Hepatic cyst,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-08-19,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CHRONIC PYELONEPHRITIS,Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010-08-19,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,LOSS WEIGHT,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LOSS APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-06,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MICROCYST  LEFT  KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-08-19,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,BRONCHIECTATIC DISEASE,Bronchiectasis,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-09-17,,ONGOING
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,INTESTINAL ANASTOMOSITIS,Intestinal anastomosis,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-10-22,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,CHOLECYSTECTOMY,,PRIOR SURGERY,RESECTION,,2011-01-13,2011-01-13,BEFORE
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,UNKNOWN,,PRIOR SURGERY,OTHER,,2011-03-09,2011-03-09,BEFORE
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,STENOCARDIA ON EXERTION,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-03-17,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-03-17,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DOLICHOSIGMOID,Dolichocolon,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2010-12-14,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HORSESHOE KIDNEY,Renal fusion anomaly,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2010-12-27,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DIVERTICULOSIS LEFT SEGMENT LARGE INTENSTINE,Diverticulum intestinal,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-14,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,SUPERFISIALIS GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-02,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHRONIC INTERNAL HEMORRHOIDS,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-14,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-14,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,CHRONIC VIRAL HEPATITIS C,Hepatitis C,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010-12-31,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,VARICOUS VIENS OF LOWER EXTREMITIES,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-03-17,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ATHEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,BUNDLE BRANCH BLOCK,Bundle branch block,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPERTENSIVE HEART DESEASE,Hypertensive heart disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,24.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-16,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,DIAPHRAGMATIC HERNIA HIATAL,Diaphragmatic hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-05,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,DRYNESS MOUTH,Dry mouth,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,CICATRIX DEFORMATION OF DUODENUM BULB,Duodenal scarring,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-05,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,BULBITIS OF DUODENUM,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-05,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,SUPERFICIAL ANTRAL GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-05,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,REFLUX ESOPHAGITIS,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-05,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,25.0,EXTERNAL HEMORRHOIDS,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-16,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-08,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,HEPATOMEGALY,Hepatomegaly,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-08-03,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,OMENTUM HEPATOSIS,Liver disorder,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,FRACTURE OF SHIN BONES,Tibia fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2007,,BEFORE
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-07-12,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,OBESSITI,Obesity,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005-02,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,POLYNEUROPATHY LOWER EXTREMITY,Polyneuropathy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010-07-12,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2003-03,,ONGOING
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1979,,BEFORE
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,CESAREAN SECTION,Caesarean section,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1984,,BEFORE
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HYPERTENSIVE HEART DISEASE,Hypertensive heart disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-04-14,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DIVERTICULUM SIGMOID COLON,Diverticulum intestinal,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-19,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,EROSIVE GASTRODUODENITIS,Gastritis erosive,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-09,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GASTROESOPHAGITIS REFLUX DISEASE,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-09,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HEMORRHOIDS,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-19,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-19,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03,,ONGOING
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-04-18,,ONGOING
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05,,ONGOING
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PUNCTION BIOPSY,Biopsy,MEDICAL HISTORY,,INVESTIGATIONS,2011-05-17,,BEFORE
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,OSTEOPOROSIS ILIUM BONE,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05-10,,ONGOING
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HEMANGIOMY RIGHT LOBE LIVER,Haemangioma of liver,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-05-10,,ONGOING
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CYST RIGHT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-05-10,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,BIOPSY LIVER,,PRIOR SURGERY,OTHER,,2011-05-27,2011-05-27,BEFORE
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,CHRONIC HEART INCOMPETENCE,Heart valve incompetence,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-05-24,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,SIGMOID POLYP,Colonic polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DIVERTICULOSIS,Diverticulum,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SUPERFICIAL GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-01-19,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BODY WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,UROLITHIASIS,Calculus urinary,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-05-24,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CYST KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-04-28,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-05-24,,ONGOING
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NEPHROGENIC HYPERTENSION,Neurogenic hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-05-24,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,DOLICHOCOLON,Dolichocolon,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,PAIN IN EPIGASTRIC AREA AND RIGHT RIBS,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,POLYPS COLON,Colonic polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,CATARRHAL BULBITIS OF DUODENUM,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DISFUNCTION CARDIAC PORTION OF THE STOMACH,Gastric disorder,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,MIXT GASTRITIS EROSIVE-HEMORRAGIVE PORTION,Gastritis erosive,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,MIXT GASTRITIS EROSIVE-HEMORRAGIVE PORTION,Gastritis haemorrhagic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,SLIDING HERNIA HEPATODUODENAL LIGAMENTUM,Hiatus hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,SPASTIC ILEUS,Ileus spastic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,PUNCTION BIOPSY LIVER,Biopsy liver,MEDICAL HISTORY,,INVESTIGATIONS,2011-06-24,,BEFORE
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-06-23,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,GIDDINESS,Dizziness,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DISKENESIA LARGE INTESTINE,Dyskinesia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-06-27,,ONGOING
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-06-23,,ONGOING
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ADENOCARCINOMA,,PRIOR SURGERY,EXPLORATORY,,2011-07-01,2011-07-01,BEFORE
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,STENOCARDIA ON EXERTION,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-06-29,,ONGOING
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,BLOCADE OF THE BUNDLE OF HIS,Bundle branch block,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-06-29,,ONGOING
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CHRONIC HEART INCOMPETENSE,Heart valve incompetence,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-06-29,,ONGOING
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ISCHEMIC HEART DISEASE GR.1,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-06-29,,ONGOING
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIC AREA GR.1,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS GR.1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04,,ONGOING
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,BIOPSY,,PRIOR SURGERY,OTHER,,2011-08-11,2011-08-11,BEFORE
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PAIN IN EPIGASTRIC AREA GR.1,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DUODENO-GASTRAL REFLUX GR.1,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-03,,ONGOING
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ATROPHIC GASTRITIS GR.1,Gastritis atrophic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-03,,ONGOING
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEAKNESS GR.1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05,,ONGOING
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LOSS WEIGHT,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-05,,BEFORE
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-05-31,,ONGOING
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CYST RIGHT AND LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-07-08,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,BILIODIGISTIVE ANASTOMOSIS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-08-03,2011-08-03,BEFORE
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,METABOLIC CARDIOMYOPHATHY,Metabolic cardiomyopathy,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-07-29,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN IN EPIGASTRIC AREA GR.1,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DUODENITIS,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-14,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DUODENOGASTRAL REFLUX GR.1,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-14,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SUPERFICIAL GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-14,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA GR.1,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,WEAKNESS GR.1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,APPETITE LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2006-03,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,ADENOCARCINOMA,,PRIOR SURGERY,OTHER,,2011-11-23,2011-11-23,BEFORE
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHRONIC HEART DECOMPENSATION,Cardiac failure chronic,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-11-21,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,ISCHEMIC HEART DISEASE(ATRIAL FIBRILLATION),Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2005-11-21,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,SUPERFICIALIS GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-16,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS GR.1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,HEPATOMEGALY,Hepatomegaly,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-10-27,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,OMENTUM HEPATOSIS,Liver disorder,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-10-27,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,TUBERCULOMA  UPPER LOBE RIGHT LUNG,Pulmonary tuberculoma,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2011-11-07,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,CHRONIC PYELONEPHRITIS,Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2011-10-27,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,TUBERCULOSIS,Tuberculosis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1961,,BEFORE
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,"DIABETES MELLITUS,GR.COMPENSATION",Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009-11-21,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,PAIN RIGHT UNDER RIB GR.1,Musculoskeletal chest pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DISCIRCULATORY ENCEPHALOPATY GR.1,Encephalopathy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-11-21,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,CYST LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-09-06,,ONGOING
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1988,,BEFORE
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1984,,BEFORE
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000,,BEFORE
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005-11-21,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,DIASTOLIC DISFUNCTION LEFT VENTRICULI,Diastolic dysfunction,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-11-14,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,CALCINOSIS MITRAL VALVE,Mitral valve calcification,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-11-14,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,PAIN IN EPIGASTRIC AREA GR.2,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,NAUSEA GR.1,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,WEAKNESS GR.1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,PAIN IN VERTEBRAL COLUMN GR.2,Spinal pain,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CHOLELITIASIS GR.1,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-11-03,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PYELOECTASIS RIGHT KIDNEY,Pyelocaliectasis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-10-26,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2007-06,,ONGOING
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,THROMB INFERIOR VENA CAVA,Vena cava thrombosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-11-03,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ADENOCARCINOMA,,PRIOR SURGERY,OTHER,,2011-12-23,2011-12-23,BEFORE
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,CHRONOTROPIC INCOMPETENCE GR.1,Chronotropic incompetence,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-12-22,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,METABOLIC CARDIOMYOPATHY,Metabolic cardiomyopathy,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-12-22,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,PAIN IN EPIGASTRIC AREA GR.1,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,WEAKNESS GR.1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,THROMBOSIS  VIEN PORTAE GR.1,Portal vein thrombosis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PAIN UNDER RIGHT RIB GR.1,Musculoskeletal chest pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2006,,ONGOING
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ADENOCARCINOMA,,PRIOR SURGERY,OTHER,,2011-12-27,2011-12-27,BEFORE
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,HYPERTENSIVE HEART DISEASE GR.2,Hypertensive heart disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-12-27,,ONGOING
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,NODULAR GOITER GR.1,Goitre,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2011-12-27,,ONGOING
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,PAIN IN EPIGASTRIC AREA GR.2,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,WEAKNESS GR.2,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-27,,ONGOING
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2005-05,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-12-09,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,BASEDOW'S GOITER,Basedow's disease,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2010-12-06,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-11,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-16,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,HEMORRHOID,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11-11,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ALLERGIC REACTIONS FOR MULTIPLE EVERYDAY AND FOOT ALLERGENS,Hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,BENIGN TUMOUR OF KIDNEY,Benign renal neoplasm,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1990,,BEFORE
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,MIOMA UTERI,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-06-08,,BEFORE
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,ENDOMETRIOSIS,Endometriosis,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010-06-08,,BEFORE
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1985,,ONGOING
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,LEFT NEPHRECTOMY,Nephrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1990,,BEFORE
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,HEMORRHOID,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-17,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1986,,BEFORE
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ALLERGIC REACTIONS FOR MULTIPLE EVERYDAY AND FOOT ALLERGENS,Hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009-11,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ECTOPIC PREGNANCY,Ectopic pregnancy,MEDICAL HISTORY,,"PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS",1986,,BEFORE
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1999,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,VARICOSE VEIN DISEASE,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,PAIN/DISCOMFORT IN MESOGASRIC,Abdominal discomfort,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2001-01-05,,ONGOING
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-05,,ONGOING
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PANCREATIC CANCER,,PRIOR SURGERY,EXPLORATORY,,2011-01-20,2011-01-20,BEFORE
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PAIN IN MESAGASTRIC (BOTH SIDE AND RADIATION TO THORACOLUMBARA),Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-10,,ONGOING
CO-101-001,CO-101-001-069-002,01069002,069,46.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,OSTEOCHONDROSIS,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PERIODICAL PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-08,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-10,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,PERIODICAL PAIN IN LEFT SCAPULA AREA,Musculoskeletal pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-08,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,UTERINE MYOMA,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1998,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,DRY COUGH,Cough,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-01-10,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,DISPNEA,Dyspnoea,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-01-10,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2010-08,,ONGOING
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,THREAT OF INTESTINAL OBSTRUCTION,,PRIOR SURGERY,EXPLORATORY,,2011-06-09,2011-06-09,BEFORE
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HEAVINESS IN EPIGASTRIUM,Epigastric discomfort,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,POLIPOSIS GASTRICA,Gastric polyps,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-28,,BEFORE
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC GASTODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-28,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,PAIN IN THORACOLUMBAR AREA,Chest pain,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,CARBOHYDRATE INTOLERANCE,Carbohydrate intolerance,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-03-23,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,PODAGRA. URATIC ARTRITIS.,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,PAIN IN THORACOLUMBAR AREA,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1972,,BEFORE
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,OBSTRUCTIVE JAUNDICE,,PRIOR SURGERY,EXPLORATORY,,2011-05-18,2011-05-18,BEFORE
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,SUBCOMPENCATORY STENOSIS OF DUODENUM,,PRIOR SURGERY,EXPLORATORY,,2011-06-29,2011-06-29,BEFORE
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-21,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,PAIN IN RIGHT HYPOHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-01,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-03,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-20,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08-03,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIABETES MELITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2007,,ONGOING
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,EPINEPHRECTOMY,,PRIOR SURGERY,RESECTION,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,NEPHRECTOMY,,PRIOR SURGERY,RESECTION,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,SPLEENECTOMY,,PRIOR SURGERY,RESECTION,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,SPLEENIC FLEXURE,,PRIOR SURGERY,RESECTION,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,SUBTOTAL DISTAL RESECTION OF PANCREAS,,PRIOR SURGERY,RESECTION,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,SUBTOTAL PROXIMAL RESECTION OF GASTRIC,,PRIOR SURGERY,RESECTION,,2010-12-01,2010-12-01,BEFORE
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1985,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MYOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN GRADE 1,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01-17,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CONSTIPATION GRADE 1,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01-17,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,FATIGUE GRADE 2,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-15,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,WEIGHT LOSS GRADE 3,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010-06,,BEFORE
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-01-10,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIABETES TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,STENTING CORONARY ARTERY,Coronary arterial stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2007-02,,BEFORE
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CHOLECYSTECTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-12-23,2010-12-23,BEFORE
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,STOMA SURGERY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-01-12,2011-01-12,BEFORE
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PROSTATE CANCER,Prostate cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2002,,BEFORE
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,VARICOSE VEINS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1982,,BEFORE
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN GRADE 1,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHRONIC DUODENITIS,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-02-04,,ONGOING
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-02-04,,ONGOING
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,FATIGUE GRADE 1,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1981,,ONGOING
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-01,,BEFORE
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN LUMBAR AREA,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-11,,ONGOING
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PARAPANCREATITIS,Pancreatitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-15,,BEFORE
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ISHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,1987,,ONGOING
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1987,,ONGOING
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HEPATITIS A,Hepatitis A,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1976,,ONGOING
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-20,,ONGOING
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-15,,ONGOING
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-15,,ONGOING
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-20,,ONGOING
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,RADICULITIS,Radiculitis,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1999,,BEFORE
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ERUCTATION,Eructation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHOLECYST POLYP,Gallbladder polyp,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BITTERNESS IN MOUTH,Dysgeusia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC BRONCHITIS,Bronchitis chronic,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1990,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,GASTRIC DISCOMFORT,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-15,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-15,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ATROPHIC GASTRITIS,Gastritis atrophic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-01,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-05,,BEFORE
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1991,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,VARICOSE VEINS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-27,,ONGOING
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2003,,BEFORE
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PARTIAL GASTRICRESECTION,Gastrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2003,,BEFORE
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,1984,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ABDOMINAL SWELLING,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-10,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,GASTRIC DISCOMFORT,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1999,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-01,,BEFORE
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2004,,ONGOING
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTENSIVE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DIAGNOSTIC,,PRIOR SURGERY,OTHER,,2011-08-19,2011-08-19,BEFORE
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CATARACT OF RIGHT EYE,Cataract,MEDICAL HISTORY,,EYE DISORDERS,1997,,BEFORE
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-15,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-27,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,FEVER,Pyrexia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-27,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-05,,BEFORE
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PROSTATITIS,Prostatitis,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,VARICOSE VEINS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1972,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-01,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,EPIGASTRIC DISCOMOIRT,Epigastric discomfort,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-17,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HEPATITIS A,Hepatitis A,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1973,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-08,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10-17,,ONGOING
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1989,,ONGOING
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NODULAR GOITER,Goitre,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1991,,BEFORE
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1991,,ONGOING
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,OBESITY,Obesity,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1991,,ONGOING
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,HYSTEROMYOMA,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1991,,ONGOING
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,POSTMENOPAUSE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1991,,ONGOING
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01,,ONGOING
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ALLERGY TO IODINE,Iodine allergy,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1965,,ONGOING
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-12,,BEFORE
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,DYSPNEA ON EXERTIONAL,Dyspnoea exertional,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01,,ONGOING
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,VARICOSE VEINS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,"LAPAROTOMY, BIOPSY OF LIVER TUMOR (MTS)",,PRIOR SURGERY,EXPLORATORY,,2010-10-18,2010-10-18,BEFORE
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,MYOCARDIODYSTROPHY,Cardiomyopathy,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-10-14,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,"PAIN, RIGHT HYPOCHONDRIUM, GRADE 1",Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,"CHRONIC DUODENITIS, REMISSION",Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,"CHRONIC GASTRITIS, REMISSION",Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,"FATIGUE, GRADE 1",Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-08,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,"CHRONIC CHOLECYSTITIS, REMISSION",Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,"CHRONIC PYELONEPHRITIS, REMISSION",Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2000,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"LOSS OF APPETITE, GRADE 1",Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYSTEROMYOMA,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2008,,ONGOING
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2008,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,"PAIN, UPPER ABDOMEN, GRADE 1",Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,"FATIGUE, GRADE 1",Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-09,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,"CHRONIC PYELONEPHRITIS, REMISSION",Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2005,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,RENAL CYSTS,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-11-03,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CYST OF THE RIGHT BREAST,Breast cyst,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2001,,BEFORE
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"CHRONIC BRONCHITIS, REMISSION",Bronchitis chronic,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1995,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2003,,ONGOING
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,RESECTION OF THE RIGHT BREAST,Mastectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2001,,BEFORE
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,"PAIN, MESOGASTRIUM, GRADE 1",Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,"CHRONIC GASTRITIS, REMISSION",Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,"FATIGUE, GRADE 1",Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-10,,ONGOING
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,BYOPSI OF METASTASIS,,PRIOR SURGERY,EXPLORATORY,,2010-12-20,2010-12-20,BEFORE
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ISCHEMIC HEART DISEASE.ATHEROSCLEROTIC CARDIOSCLEROSIS.,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-01,,ONGOING
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ISCHEMIC HEART DISEASE.ATHEROSCLEROTIC CARDIOSCLEROSIS.,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-01,,ONGOING
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,DIABETIS MELITUS TYPE,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-07,,ONGOING
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,GIRDLE PAIN IN THE BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-01,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,"LAPAROTOMY,BYOPSI OF METASTASIS",,PRIOR SURGERY,EXPLORATORY,,2010-12-21,2010-12-21,BEFORE
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,"ISCHEMIC HEART DISEASE,ATHEROSCLEROTIC CARDIOSCLEROSIS",Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,"ISCHEMIC HEART DISEASE,ATHEROSCLEROTIC CARDIOSCLEROSIS",Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CHRONIC CHOLECYSTISIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GIRDLE PAIN IN THE BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PROSTATE ADENOMA,Prostatic adenoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CYST OF THE LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL AORTIC ATHEROSCLEROSIS,Aortic arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,EXCISIONAL BIOPSY OF LYMPH NODES SUPRACLAVICULAR AREA,,PRIOR SURGERY,OTHER,,2011-02-02,2011-02-02,BEFORE
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,EXTERNAL-INTERNAL DRAINAGE OF BILE DUCTS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-11-17,2010-11-17,BEFORE
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PAIN IN THE EPIGASTIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC GASTRODYODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,LAPARASCOPIC CHOLESYCTENTEROSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-01-17,2011-01-17,BEFORE
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,RESECTION OF LIVER METASTASES,,PRIOR SURGERY,RESECTION,,2011-01-17,2011-01-17,BEFORE
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ATHEROSCLEROSIS IN AORTA AND CORONARY ARTERIES,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PAIN IN THE EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,DUODENTIS IN THE BULB OF DUODENUM,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ARTERIAL HYPERTENSION GRADE 2,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,CHOLECYSTOJEJUNOSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-03-13,2011-03-13,BEFORE
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANGINA FUNCTIONAL CLASS II,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ATHEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,GIRDLE PAIN IN THE BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01-15,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CEREBROVASCULAR DISEASE,Cerebrovascular disorder,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DISCIRCULATORY ENCEPHALOPATHY,Encephalopathy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HYPERTONIC DISEASE,Hypertonia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"FORMING OF HOLITSISTODUODENOANASTOMOSIS, BIOPSY OF NODE IN LIVER",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-12-12,2011-12-12,BEFORE
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIABETES MELLITUS SYMPTOMATIC TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BACKPAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION GRADE 2,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,"HOLEDOHOSTOMY, BIOPSY OF PANCREAS, AND METASTASIS ON LIVER",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2012-01-19,2012-01-19,BEFORE
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,PAIN IN THE EPIGASTIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,SYMPTOMATIC DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ACUTE ISCHEMIC ATTACK,Transient ischaemic attack,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2010,,ONGOING
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-06,,BEFORE
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DUCTUS CHOLEDOCHUS DRAINAGE,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-11-25,2010-11-25,BEFORE
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LAPAROSCOPIC CHOLECYSTECTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-11-25,2010-11-25,BEFORE
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CORONAL HEART DISEASE (LATENT MYOCARDIAL ISCHEMIA),Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,OCCASIONAL PAINS IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRANICAL ATROPHIC GASTRITIS,Gastritis atrophic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,FATIQUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11,,ONGOING
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONICAL OBSTRUCTIVE BRONCHITIS,Bronchitis chronic,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1980,,ONGOING
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,RECURRING PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05,,ONGOING
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,"UROLITHIASIS, CALCULOUS HYDRONEPHROSIS",Calculus urinary,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,"UROLITHIASIS, CALCULOUS HYDRONEPHROSIS",Hydronephrosis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC BRONCHITIS,Bronchitis chronic,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2005,,ONGOING
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,"CHOLECYSTECTOMY, OMENTECTOMY,  OMPHALOCELE REPAIR",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-08-24,2011-08-24,BEFORE
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,PANCREATIC CYST DRAINAGE,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-07-28,2011-07-28,BEFORE
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CORONARY HEART DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,CHOLECYSTECTOMY AND OMPHALOCELE REPAIR,Exomphalos,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2011-08-24,,BEFORE
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,OMPHALOCELE,Exomphalos,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2000,,BEFORE
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,STOMACH ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CALCULOUS CHOLECYSTITIS,Cholecystitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-04,,BEFORE
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2008,,ONGOING
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CHOLECYSTECTOMY AND OMPHALOCELE REPAIR,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-08-24,,BEFORE
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIQUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,FATIQUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01,,ONGOING
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DIABETES TYPE 2,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,BEFORE
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTONY,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NA,,PRIOR SURGERY,OTHER,,2011-05-16,2011-05-16,BEFORE
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MILUTUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PALEOTIV TREATMENT,,PRIOR SURGERY,OTHER,,2012-01-16,2012-01-16,BEFORE
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,APPENDECTOMIA,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1974,,BEFORE
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,AMPUTATION OF UTERI,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2007,,BEFORE
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PHLEBECTOMIA OF BOTH LEG,Phlebectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1990,,BEFORE
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,POSTMENOPAUSE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2006,,ONGOING
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CESAREAN SECTION,Caesarean section,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1986,,BEFORE
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HEPATICOEUNOSTOMIA,Hepaticojejunostomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-11-17,,ONGOING
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,MENOPAUSA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2000,,ONGOING
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,OPERATION FOR CYST OF OVARII,Ovarian cystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1980,,BEFORE
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSIA,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,"RIGHT HEMICOLECTOMY, RIGHT OVARECTOMY, RESECTION OF SMALL INTESTINES",,PRIOR SURGERY,RESECTION,,2010-04-22,2010-04-22,BEFORE
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,CHRONIC GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC PYELONEPHRITIS,Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1990,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHRONIC CYSTITIS,Cystitis noninfective,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,BRONCHIAL ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1980,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2005,,ONGOING
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DIAGNOSTICS,,PRIOR SURGERY,EXPLORATORY,,2011-03-03,2011-03-03,BEFORE
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ISCHEMIC HEARD DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHRONIC GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,MIOMA UTERI,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2004,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CEREBRO-VASCULAR DISEASE,Cerebrovascular disorder,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CHRONIC CYSTITIS,Cystitis noninfective,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,EROSION OF CERVIC UTERI,Uterine cervical erosion,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,1977,,BEFORE
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,MENOPAUZA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2003,,ONGOING
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-078-007,01078007,078,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BIOPSIA,,PRIOR SURGERY,EXPLORATORY,,2011-04-15,2011-04-15,BEFORE
CO-101-001,CO-101-001-078-007,01078007,078,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1997,,ONGOING
CO-101-001,CO-101-001-078-007,01078007,078,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,MENOPAUSA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2000,,ONGOING
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NO,,PRIOR SURGERY,RESECTION,,2010-10-19,2010-10-19,BEFORE
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHRONIC ULCER,Ulcer,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,1980,,ONGOING
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTONIA,Hypertonia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MENOPAUSA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1997,,ONGOING
CO-101-001,CO-101-001-078-009,01078009,078,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,RESECTION OF TYREOID GLAND,Thyroidectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2005,,ONGOING
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,N,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-10-18,2011-10-18,BEFORE
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CHRONIC ULCER OF DUODENUM,Duodenal ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERTONIC DISEASE,Hypertonia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ATEROSCLEROSIS,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HYPERTROPHY OF LEFT VENTRICULAR,Left ventricular hypertrophy,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-09-14,,ONGOING
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ESOFAGEAL REFLUX,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-06-29,,ONGOING
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ESOFAGITIS,Oesophagitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09-06,,ONGOING
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,POLYP OF RECTUM,Rectal polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09-07,,ONGOING
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,S/P RIGHT SIDE CHEST RIBS FRACTURE,Rib fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2010,,BEFORE
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CYSTS OF BOTH KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-09-09,,ONGOING
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ASCITES,Ascites,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08-31,,ONGOING
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-02-22,,BEFORE
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1990,,ONGOING
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1978,,ONGOING
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DOUDENITIS,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09-07,,ONGOING
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CYST OF LEFT OVARIUM,Ovarian cyst,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010-09-29,,ONGOING
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1989,,ONGOING
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,HUPERBILIRUBINEMIA,,PRIOR SURGERY,OTHER,,2009-11-04,2009-11-04,BEFORE
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,S/P HYDRO PNEUMOTHONEX,Hydropneumothorax,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-08-30,,BEFORE
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,S/P PLEURAL EFFUSION,Pleural effusion,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-08-25,,BEFORE
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,S/P PLEURAL PUNCTION,Thoracic cavity drainage,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-08-25,,BEFORE
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LIPOMA,Lipoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2008-12-10,,ONGOING
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CYST OF RIGHT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MASTOPATHY,Breast disorder,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2008-12-10,,ONGOING
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2008,,ONGOING
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHOLEDOCHODUODENO STOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-01-18,2011-01-18,BEFORE
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,KIDNEY CYSTES,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,"BIOPSY OF TUMOR IN PANCREASE, MTS IN LIVER, CATHETERIZATION OF A.HEPATICA PROPRIA, A.LIENALIS, OMENTOPANCREATOPEXIA",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-12-28,2010-12-28,BEFORE
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,EXTRASYSTOLIC ARRHYTHMIA,Arrhythmia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ATHEROSCLEROTIC KARDIOSKLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HEART FAILURE,Cardiac failure,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,IHD,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,S/P A LIENALIS CATHETERIZATION,Arterial catheterisation,MEDICAL HISTORY,,INVESTIGATIONS,2010-12-28,,BEFORE
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,METROFIBROMA,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ECHIMOSIS IN GASTRIC MUCOSA,Ecchymosis,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-12-13,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1998,,ONGOING
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,S/P OMENTOHEPATOPEXY - SHELTERING OF THE LIVER BY THE GREATER OMENTUM,Gastrointestinal surgery,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-12-28,,BEFORE
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ESSENTIAL ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-12-15,,ONGOING
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12,,ONGOING
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,POOR APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,TYPE 2 DIABETES MELLITUS,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1991,,ONGOING
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,COMBINED DISTAL GASTRECTOMY WITH SPLENECTOMY AND RESECTION SPLENIC FLEXURE,,PRIOR SURGERY,RESECTION,,2010-10-06,2010-10-06,BEFORE
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,EXTRASYSTOLIC ARRHYTHMIA,Arrhythmia,MEDICAL HISTORY,,CARDIAC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,FRACTURE OF THE LEFT LEG AND LEFT ARM,Lower limb fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1985,,BEFORE
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FRACTURE OF THE LEFT LEG AND LEFT ARM,Upper limb fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1985,,BEFORE
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,IHD,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-20,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CICATRICIAL DEFORMITY OF THE DUODENAL BULB,Duodenal scarring,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1969,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DUODENAL ULCER,Duodenal ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1969,,BEFORE
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DUODENOGASTRIC REFLUX,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1969,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANTRAL ERYTHEMATOSUS GASTROPATHY,Gastric mucosa erythema,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-06,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,REFLUX ESOPHAGITIS,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1969,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,GASTROESOPHAGEAL PROLAPSE,Hiatus hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-06,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LOSS WEIGHT,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-06,,ONGOING
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,STROKE/CVA,Cerebrovascular accident,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PAINE IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-01,,ONGOING
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-01,,ONGOING
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,TYPE 2 DIABETES MELLITUS,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09-22,,ONGOING
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,"CHOLEDOCHODUODENOSTOMY, CHOLECYSTECTOMY",,PRIOR SURGERY,OTHER,,2011-05-20,2011-05-20,BEFORE
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,RIGHT SIDE HEMICOLONECTOMY FOR COLORECTAL  CANCER II ST,Colorectal cancer stage II,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1974,,BEFORE
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYSTERECTOMY FOR UTERINE CANCER II ST,Uterine cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1994,,BEFORE
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHRONIC OBSTRUCTIVE PULMONARY DISEASE 2 GRADE,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010,,ONGOING
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1994,,ONGOING
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ABDOMINAL DISTENTION,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,PAINE IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAINE IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DUODENAL BULBITIS,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DUODENOGASTRIC REFLUX (REMISSION),Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,EROSIV GASTRITIS,Gastritis erosive,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2007,,ONGOING
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHOLEDOCHODUODENOSTOMY,,PRIOR SURGERY,OTHER,,2010-11-22,2010-11-22,BEFORE
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11,,ONGOING
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,LAPAROSCOPIC BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-10-24,2011-10-24,BEFORE
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL DISTENTION,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PAIN IN HYPOCHONDRIUM RIGHT SIDE,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,POOR APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,CHOLECYSTOEUNTEROSTOMY,,PRIOR SURGERY,OTHER,,2011-11-15,2011-11-15,BEFORE
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,PERCUTANEOUS CHOLECYSTOSTOMY,,PRIOR SURGERY,OTHER,,2011-09-02,2011-09-02,BEFORE
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,CHD ATHEROSCLEROTIC CARDIOSCLEROSIS NYHA 1,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,CHD ATHEROSCLEROTIC CARDIOSCLEROSIS NYHA 1,Heart disease congenital,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2002,,ONGOING
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,PAINE IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-027,01079027,079,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08,,ONGOING
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10,,ONGOING
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DUODENOGASTRIC REFLUX,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-06,,ONGOING
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-06,,ONGOING
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,UMBILICAL HERNIA,Umbilical hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-22,,BEFORE
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,GENERAL WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01,,ONGOING
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LOSS APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2004,,ONGOING
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHRONIC DUODENITIS,Duodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-10,,ONGOING
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-10,,ONGOING
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHRONIC HEMORRHOIDS,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-27,,ONGOING
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CATHARRAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-27,,ONGOING
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-06-29,,ONGOING
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,POST-MENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2003,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,CYTOREDUCTIVE BLASTOMA REMOVAL FROM RETROPERITONEAL SPACE,,PRIOR SURGERY,RESECTION,,2010-09-16,2010-09-16,BEFORE
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPOFUNCTION OF THYROID GLAND,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1973,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,PAIN IN EPIGASTRIA AND HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DUODENOGASTRIC REFLUX,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09-23,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,VARICOSE VEINS OF ESOPHAGUS,Varices oesophageal,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-06-03,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CHRONIC CALCULOUS CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-08-31,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,VIRAL HEPATITIS,Hepatitis viral,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1983,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BILATERAL HYPOSTATIC PNEUMONIA,Pneumonia,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010-09-03,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CYST OF RIGHT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-10-19,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYDROTHORAX LEFT SIDE,Hydrothorax,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-09-03,,ONGOING
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,POSTMENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2008,,ONGOING
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CHOLECYSTOJEJUNOSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-12-24,2010-12-24,BEFORE
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,LYMPH NODES OF RETROPERITONEAL SPACE,,PRIOR SURGERY,OTHER,,2010-12-24,2010-12-24,BEFORE
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ALLERGIC REACTION TO NOVOCAINUM,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1980,,ONGOING
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12-27,,ONGOING
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,OSTEOCHONDROSIS,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CRANIOCEREBRAL INJURY,Brain injury,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1995,,BEFORE
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,CYST OF LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-01-12,,ONGOING
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,RIGHT HAND & RIGHT KNEE TENDON PLASTY,Tendon operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995,,BEFORE
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2008-08-21,,ONGOING
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,CHOLECYSTECTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-03-26,2010-03-26,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,CHOLECYSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-03-12,2010-03-12,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,PANCREATODUODENAL RESECTION,,PRIOR SURGERY,RESECTION,,2010-07-07,2010-07-07,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-07,,ONGOING
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CHRONIC PANCREATTITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-07-07,,ONGOING
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,CHOLECYSTITIS,Cholecystitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-03-12,,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,RIGHTSIDE NEPHROPTOSIS,Nephroptosis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-01-11,,ONGOING
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,POSTMENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2008,,ONGOING
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,HEPATIC DUCT DRAINAGE,Bile duct stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-03-26,,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-03-26,,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,RESECTION OF TWO THIRD OF STOMACH,Gastrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-07-07,,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,JEJUNUM EXCISION,Jejunectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-07-07,,BEFORE
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,PANCREATODUODENAL RESECTION,Pancreaticoduodenectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-07-07,,BEFORE
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ABDOMINAL CAVITY DRAINING,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-01-21,2011-01-21,BEFORE
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CORE BIOPSY OF PANCREAS HEAD,,PRIOR SURGERY,EXPLORATORY,,2011-01-21,2011-01-21,BEFORE
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LOPERATOMY. CHOLECYSTOJEJUNOSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-01-21,2011-01-21,BEFORE
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01-19,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,BIOPSY OF FORMATION IN RETROPERITONEAL  AREA,,PRIOR SURGERY,EXPLORATORY,,2011-03-31,2011-03-31,BEFORE
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,HEART FAILURE,Cardiac failure,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-03-16,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,IHD,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-03-16,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,DODENUM ULCER,Duodenal ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1994-03,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,GASTRIC POLYPES,Gastric polyps,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-15,,BEFORE
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-22,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-16,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-02-16,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,MYOMA OF WOMB BODY,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1995,,BEFORE
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,OVARIAN CYSTS,Ovarian cyst,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000-01-10,,BEFORE
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NEPHRECTOMY LEFT SIDE,Nephrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-07-11,,BEFORE
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1997,,ONGOING
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DUODENOGASTRIC  REFLUX,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-01,,ONGOING
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NIDAL GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-01,,ONGOING
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHRONIC CALCULOUS CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1993-02-16,,ONGOING
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,RIGHT NIDAL MASTOPATHY,Breast disorder,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-05-05,,BEFORE
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1995-01-23,,ONGOING
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,DIAGNOSTIC LAPAROTOMY. BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-04-26,2011-04-26,BEFORE
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FOCAL CATARAL GASTRODUODENOPATHY,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-21,,ONGOING
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-14,,ONGOING
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CATARRHAL PAPILLITIS,Papillitis,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-21,,ONGOING
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,CHRONIC CALCULOUS CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-04-14,,ONGOING
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,DIFFUSIVE CHANGES OF HEPAR PARENCHYMA,Liver disorder,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-04-14,,ONGOING
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DIAGNOSTIC TREPANATION,,PRIOR SURGERY,OTHER,,2011-05-19,2011-05-19,BEFORE
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ATHEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,VENTRAL HERNIA,Abdominal hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1961,,ONGOING
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-31,,ONGOING
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CHRONIC  CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-03-23,,ONGOING
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,POSTMENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1974-03,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,N/A,,PRIOR SURGERY,OTHER,,2011-06-08,2011-06-08,BEFORE
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ATEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HEART FAILURE,Cardiac failure,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIFFUSE-NODULAR GOITER,Goitre,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1997-01-16,,BEFORE
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2004-05-07,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CHRONIC GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2004-05-07,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2004-05-07,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ASTHENIC-NEUROTIC SYNDROME,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2004-05-07,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-05-24,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,POST-MENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,CHOLECYSTECTOMY,,PRIOR SURGERY,RESECTION,,2011-08-03,2011-08-03,BEFORE
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LAPAROTOMY,,PRIOR SURGERY,RESECTION,,2011-08-03,2011-08-03,BEFORE
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-11,,ONGOING
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-07-11,,ONGOING
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,FATTY HEPATOSIS,Liver disorder,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-07-11,,ONGOING
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CYST OF LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-08-30,,ONGOING
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DISTAL PANCREAS RESECTION,,PRIOR SURGERY,RESECTION,,2010-12-07,2010-12-07,BEFORE
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,TREPAN BIOPSY OF PANCREATIC GLAND,,PRIOR SURGERY,EXPLORATORY,,2010-11-30,2010-11-30,BEFORE
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PERIODICAL PAIN IN RIGHT & LEFT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-08,,ONGOING
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1966,,BEFORE
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERGLYCEMIA,Hyperglycaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,POST-MENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1979,,ONGOING
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,TREPAN BIOPSY OF LIVER,,PRIOR SURGERY,EXPLORATORY,,2011-07-25,2011-07-25,BEFORE
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DUODENOGASTRIC REFLUX,Duodenogastric reflux,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-24,,ONGOING
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIFFUSIVE GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-24,,ONGOING
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-07-12,,ONGOING
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,POST-MENOPAUSAL FEMALE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2005,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,RIGHT BUNDLE-BRANCH BLOCK,Bundle branch block right,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-09-05,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CHRONIC HEART FAILURE,Cardiac failure chronic,MEDICAL HISTORY,,CARDIAC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LEFT VENTRICULAR HYPERTROPHY,Left ventricular hypertrophy,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-09-05,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHRONIC ACALCULOUS CHOLECYSTITIS,Cholecystitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-08-12,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC NONCALCULOLIS CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-08-12,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HEMANGIOMA L3,Spinal haemangioma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-08-18,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,UROLITHIASIS,Calculus urinary,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-08-12,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYDRONEPHROSIS OF LEFT KIDNEY,Hydronephrosis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-08-12,,ONGOING
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1993,,ONGOING
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,LAPARATOMY.CHOLECYSTOJEJUNOSTOMY,,PRIOR SURGERY,OTHER,,2011-01-25,2011-01-25,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,TREPAN BIOPSY OF LIVER,,PRIOR SURGERY,EXPLORATORY,,2011-08-25,2011-08-25,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-11,,ONGOING
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-31,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-01-05,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HEPATIC STEATOSIS,Hepatic steatosis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SECONDARY DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08-25,,ONGOING
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,LEIOMYOMA OF THE WOMB BODY,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2002,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2004,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,FRESH FROZEN PLAZMA TRANSFUSION,Blood product transfusion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-01-19,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2004,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,PACKED RED BLOOD CELL TRANSFUSION,Packed red blood cell transfusion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-02-09,,BEFORE
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PACKED RED BLOOD CELL TRANSFUSION,Packed red blood cell transfusion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-02-15,,BEFORE
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LAPAROTOMY. CHOLECYSTOJEJUNOSTOMY. BIOPSY OF PANCREAS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-05-20,2010-05-20,BEFORE
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,CICATRICIAL DEFORMITY OF DUODENUM BULB,Duodenal scarring,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-05-18,,ONGOING
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,FOCAL GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-05-18,,ONGOING
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,PSEUDOTUMOROUS PANCREATITIS,Pancreatitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-20,,ONGOING
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,PAIN IN LUMBAR AREA,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PAIN SYNDROME IN LUMBAR AREA & LEFT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FOCAL GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-02,,ONGOING
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NIDAL BULBITIS,Gastrointestinal inflammation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-02,,ONGOING
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CHRONIC HEMORRHOID,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-12,,ONGOING
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CATARRHAL COLITIS,Irritable bowel syndrome,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-12,,ONGOING
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN SYNDROME IN LUMBAR AREA & LEFT HYPOCHONDRIUM,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,"LAPAROTOMY, BIOPSY OF LIVER MTS,  DRAINING OF ABDOMINAL CAVITY",,PRIOR SURGERY,EXPLORATORY,,2011-09-06,2011-09-06,BEFORE
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SPLENOMEGALY,Splenomegaly,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-30,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,TREPAN-BIOPSY PF TUMOR IN LEFT LIVER LOBE,,PRIOR SURGERY,EXPLORATORY,,2011-10-18,2011-10-18,BEFORE
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,CHRONIC ATROPHIC GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008-06-24,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008-06-24,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,BREAST FIBROADENOSIS,Fibroadenoma of breast,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-14,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LOCAL BREAST ADENOSIS,Fibroadenoma of breast,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-14,,BEFORE
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CENTRAL PAIN SYNDROME,Central pain syndrome,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CYST IN LEFT BREAST,Breast cyst,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-11-14,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,POSTMENOPAUSE,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2011-07,,ONGOING
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DRAINING OF ABDOMINAL CAVITY,Abdominal cavity drainage,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-06-27,,BEFORE
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ELECTROCONIZATION  OF UTERUS NECK,Cervical conisation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-11-11,,BEFORE
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-06-27,,BEFORE
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,LAPAROTOMY,Laparotomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-06-27,,BEFORE
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,"CHOLECYSTOGASTROSTOMY, BIOPSY OF LIVER, DRAINING OF ABDOMINAL CAVITY",,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-10-28,2011-10-28,BEFORE
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN SYNDROME IN EPIGASTRIA,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PANCREATICODUODENAL RESECTION,,PRIOR SURGERY,RESECTION,,2011-01-05,2011-01-05,BEFORE
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC CALCULOUS CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1990,,BEFORE
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,KIDNEYS CYSTS,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-12-13,,ONGOING
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DOFFISE CARDIOSCLEROSIS,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,"LAPAROSCOPY, BIOPSY MTS LESIONS IN ABDOMINAL MEMBRANE",,PRIOR SURGERY,EXPLORATORY,,2011-12-09,2011-12-09,BEFORE
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SINUS ARRHYTHMIA WITH DIFFUSE CHANGES OF MYOCARD,Sinus arrhythmia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-12-07,,ONGOING
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FOCAL ERYTHEMATIC GASTROPATHY,Gastric mucosa erythema,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-23,,ONGOING
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-25,,ONGOING
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHRONIC CHOLECYSTITIS,Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-11-25,,ONGOING
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DIFFUCE CHANGES OF LIVER,Liver disorder,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-11-25,,ONGOING
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2006,,ONGOING
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PERCUTANEOUS BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-12-15,2011-12-15,BEFORE
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CONGESTIVE GASTROPATHY,Portal hypertensive gastropathy,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-08,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,BIOPSY OF FORMATION IN RIGHT BREAST & RIGHT AXILLARY LYMPH NODE,,PRIOR SURGERY,EXPLORATORY,,2012-01-03,2012-01-03,BEFORE
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,REMOVAL OF TUMOR AT FRONT ABDOMINAL WALL,,PRIOR SURGERY,RESECTION,,2011-09-02,2011-09-02,BEFORE
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PERIODICAL PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PERIODICAL GENERAL FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LATE EFFECTS OF ACUTE CEREBRAL CIRCULATION DISODER,Cerebrovascular disorder,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1995,,ONGOING
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2009,,BEFORE
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,"LAPAROTOMY, TREPAN BIOPSY OF NEOPLASM",,PRIOR SURGERY,EXPLORATORY,,2012-02-02,2012-02-02,BEFORE
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-21,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CORONARY HEART DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2012-01-27,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NODULAR GOITER,Goitre,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2012-02-21,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,PAIN SYNDROME  IN UPPER PARTS OF ABDOMEN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,INSIGNIFICANT GENERAL FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HEPATIC STEATOSIS,Hepatic steatosis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2011-03-25,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DYSCHOLIA,Bile output abnormal,MEDICAL HISTORY,,INVESTIGATIONS,2012-01-30,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-01-27,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ATHEROSCLEROSIS,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2012-01-27,,ONGOING
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2012-01-27,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,PUNCTURE BIOPSY OF LIVER MTS,,PRIOR SURGERY,EXPLORATORY,,2012-02-15,2012-02-15,BEFORE
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LEFT ANTERIOR HEMIBLOCK,Bundle branch block left,MEDICAL HISTORY,,CARDIAC DISORDERS,2012-02-13,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,INCOMPLETE RIGHT BUNDLE-BRANCH BLOCK,Bundle branch block right,MEDICAL HISTORY,,CARDIAC DISORDERS,2012-02-13,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PERIODICAL PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,SUPERFICIAL GASTRODUODENITIS,Gastroduodenitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-15,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INSIGNIFICANT GENERAL FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,TUBERCULOSIS,Tuberculosis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1998,,BEFORE
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CALCIFICATION IN LUNGS,Pulmonary calcification,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-14,,ONGOING
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,TREPANBIOPSY OF LIVER,,PRIOR SURGERY,EXPLORATORY,,2012-03-07,2012-03-07,BEFORE
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,PAIN SYNDROME IN LEFT & RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,WEIGHT LOSS UP TO 8 KG,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-10,,ONGOING
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2010-10,,ONGOING
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011,,BEFORE
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,"TREPAN-BIOPSY OF PANCREAS, LIVER MTS",,PRIOR SURGERY,EXPLORATORY,,2012-03-13,2012-03-13,BEFORE
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,PERIODICAL PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DYSPLASIA OF IVTH RIB RIGHT SIDE,Dysplasia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-26,,ONGOING
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,GENERAL FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01,,ONGOING
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,VIRAL HEPATITIS,Hepatitis viral,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1981,,BEFORE
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-01,,BEFORE
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1981,,BEFORE
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,LAPAROTOMY. LIVER METASTASIS BIOPSY. PRIMARY TUMOR BIOPSY.GANGLYOSPLANCHNICECTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2010-09-22,2010-09-22,BEFORE
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SPLENIC CYSTIS,Splenic cyst,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-09-29,,ONGOING
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHF STAGE 1,Cardiac failure chronic,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-09-29,,ONGOING
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ISCHEMIC HEART DESEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-09-29,,ONGOING
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN SYNDROME,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009-09,,ONGOING
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PANCREATIC TAIL CYSTS,Pancreatic cyst,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09-29,,ONGOING
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LEFT KIDNEY CYSTIS,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-09-29,,ONGOING
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-10-12,,ONGOING
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,MENOPAUSA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2001,,ONGOING
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,"SUBTOTAL RESECTION OF PANCREAS, SPLENECTOMY",,PRIOR SURGERY,RESECTION,,2010-11-02,2010-11-02,BEFORE
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTONIC DISEASE,Hypertonia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010-10-25,,ONGOING
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1990,,ONGOING
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LAPARATOMY WITH LYMPH NODES BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-06-21,2011-06-21,BEFORE
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ABDOMINAL PAIN SYNDROME,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DYSPEPSIA,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,MYOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,UMBILICAL HERNIA,Umbilical hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-29,,BEFORE
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DIABETIS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ADENOMA OF PROSTATA,Prostatic adenoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-09-29,,ONGOING
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHOLECYSTOENTEROSTOMY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-12-01,2011-12-01,BEFORE
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ECTOPIC PREGNANCY,Ectopic pregnancy,MEDICAL HISTORY,,"PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS",2000-06-16,,BEFORE
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GASTRITIS IN REMISSION STAGE,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2007,,BEFORE
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANGINA PECTORIS,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,1985,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,1985,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ISCHEMIC NEUROPATHY OF RIGHT EYE,Optic ischaemic neuropathy,MEDICAL HISTORY,,EYE DISORDERS,2010-11-01,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-09,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-14,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,EROSIVE GASTRITIS,Gastritis erosive,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-09,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,VIRAL HEPATITIS,Hepatitis viral,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1945,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,DIABETUS MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007-01-01,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,OSTEOCHONDROSIS,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,POLYPS OF CERVIX UTERI,Cervical polyp,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2002,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,MENOPOUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1983,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,SECTORAL RESECTION OF RIGHT BREAST,Mastectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1982,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,RESECTION OF RECTUM,Resection of rectum,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1993-07-08,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,VENESECTION OF LEFT LEG'S VEINS,Venipuncture,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-09-09,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009-01-01,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ACUTE TROMBOPHLEBITIS OF LEFT LEG'S VEINS,Thrombophlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,1994,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,TROMBOPHLEBITIS OF RIGHT ARM'S,Thrombophlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-01-31,,BEFORE
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,VARICOSE VEINS,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,2010-09-01,,ONGOING
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,VARICOSE VEINS OF LEFT LEG,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1998,,BEFORE
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CORONARY CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,1988,,ONGOING
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,MYOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,1988,,BEFORE
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MYOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,MYOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,BEFORE
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ISCHEMIC HEART DISEASEE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,1988,,ONGOING
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-01,,ONGOING
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,OSTEOCHONDROSIS OF VERTEBRAE  WITH SCHMORL'S NODULE,Intervertebral disc disorder,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-19,,ONGOING
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,OSTEOCHONDROSIS OF VERTEBRAE  WITH SCHMORL'S NODULE,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-19,,ONGOING
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HERNIOPLASTYKA OF RIGHT INGUINAL HERNIA,Inguinal hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-14,,BEFORE
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ALLERGY OF ACIDUM MEPHENAMINICUM,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2010-07-01,,ONGOING
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PULMONARY EMBOLISM OF BOTH LUNGS,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-08,,BEFORE
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ATEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-16,,ONGOING
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PANCREATITIS,Pancreatitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2008,,BEFORE
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CHRONIC HEPATITIS,Chronic hepatitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ALLERGY REACTION ON TETANUS VACCINE,Allergy to vaccine,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,OSTEOCHONDROSIS,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,HERNIOTOMY,Hernia repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2009,,BEFORE
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,POSTINFARCTION CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,MIOCARDIAL INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,2010,,BEFORE
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,1980,,BEFORE
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-01,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DUODENUM ULCER,Duodenal ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-01,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GASTRIC ULCER,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-01,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CHRONIC PANCREATITIS,Pancreatitis chronic,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-01,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,POSTCHOLECYSTECTOMIC SYBDROME,Post cholecystectomy syndrome,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,POSTTRAUMATIC OSTEOMYELITIS OF LEFT PATELLA,Osteomyelitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1990,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC PYELONEPHRITIS,Pyelonephritis chronic,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1990,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,KNEE PAIN,Arthralgia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007-11-01,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-08-01,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,CHRONIC COUGH,Cough,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1990,,ONGOING
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1990,,BEFORE
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,POSTINFARCTION CARDIOSCLEROSIS,Infarction,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LAPAROTOMY,,PRIOR SURGERY,EXPLORATORY,,2011-11-03,2011-11-03,BEFORE
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,GOITER,Goitre,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,SCOLIOSIS OF SPINE,Scoliosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1958-02-09,,ONGOING
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CATARACT OF RIGHT EYE,Cataract,MEDICAL HISTORY,,EYE DISORDERS,2011-02-25,,BEFORE
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-02,,ONGOING
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-02,,ONGOING
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ISCHEMIC STROKE,Ischaemic stroke,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2006-08-18,,BEFORE
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,MICROSTROKE,Transient ischaemic attack,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CYST OF LEFT KIDNEY,Renal cyst,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,RASH ON LEGS AND HANDS,Rash,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-02,,ONGOING
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,TREPANBIOPSY,,PRIOR SURGERY,OTHER,,2011-11-22,2011-11-22,BEFORE
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ABDOMEN PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-31,,ONGOING
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-28,,ONGOING
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,TOXIC ENTEROCOLIT,Enterocolitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-31,,BEFORE
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,FRACTURE OF RIBS AND CLAVICULAE,Clavicle fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1990,,BEFORE
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,FRACTURE OF RIBS AND CLAVICULAE,Rib fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1990,,BEFORE
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,OSTEOCHONDROSIS,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,GASTRO- AND CHOLECYSTOENTEROTOMIA,,PRIOR SURGERY,OTHER,,2011-12-05,2011-12-05,BEFORE
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ATEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-01,,ONGOING
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ESOPHAGEAL VARICOSE VEINS DILATATION,Oesophageal dilatation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-05,,ONGOING
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,COLON CANCER,Colon cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2003,,BEFORE
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,RENAL CANCER,Renal cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2001,,BEFORE
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,RIGHT HEMICOLECTOMY,Colectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2003,,BEFORE
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEPHRECTOMY,Nephrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2001,,BEFORE
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,EXCISION OF ADENOMA PROSTATE,Prostatectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010,,BEFORE
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LAPAROCSOPY,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2012-01-30,2012-01-30,BEFORE
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ABDOMENAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-14,,ONGOING
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,OSTEOCHONDROSIS,Osteochondrosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ABSCESS OF CEREBRUM,Brain abscess,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1993,,BEFORE
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,VIRAL HEPATITIS,Hepatitis viral,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1980,,BEFORE
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,MICROSTROKE,Transient ischaemic attack,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,MENOPAUSA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2002,,ONGOING
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,HYPERTENSION DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-02-28,2011-02-28,BEFORE
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-01,,ONGOING
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC COLITIS,Colitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIAPHRAGM HERNIA,Diaphragmatic hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-10,,ONGOING
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-04-18,2011-04-18,BEFORE
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DUODENAL ULCER,Duodenal ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2000,,BEFORE
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,WEAKNESS THROUGHOUT THE BODY,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03,,ONGOING
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HEPATITIS A,Hepatitis A,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1987,,BEFORE
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTONIC DISEASE,Hypertonia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1981,,ONGOING
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ISCHEMIC STROKE,Ischaemic stroke,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1997,,BEFORE
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LEFT NEPHRECTOMY,Nephrectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-09-20,,BEFORE
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-06-16,2011-06-16,BEFORE
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ATHEROSCLEROTIC CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02,,ONGOING
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PAIN LOWER BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,WEAKNESS OF LOWER EXTREMITIES,Muscular weakness,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-10,,ONGOING
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-09-08,2011-09-08,BEFORE
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-06,,ONGOING
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-11-01,2011-11-01,BEFORE
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-10-28,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-10-28,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-10-11,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CHRONIC ECZEMA,Eczema,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,1968,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MENOPAUSAL,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1981,,ONGOING
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERTENSIVE DISEASE,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-10-28,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HOLETSISTOENTEROANASTOMOSIS,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-09-22,2011-09-22,BEFORE
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,AORTIC VALVE STENOSIS,Aortic valve stenosis,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-09-15,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,FORWARD HEART FAILURE,Cardiac failure,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-09-15,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-09-15,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HEMORRHOIDS,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,MENOPAUSAL,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1986,,ONGOING
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIFFUSE CARDIOSCLEROSIS,Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-09-15,,ONGOING
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,10.0,BIOPSY,,PRIOR SURGERY,OTHER,,2011-11-29,2011-11-29,BEFORE
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,8.0,CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-11-28,,ONGOING
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,9.0,CORONARY HEART DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-11-28,,ONGOING
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,4.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,3.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,5.0,HEPATITIS B,Hepatitis B,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1966,,BEFORE
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,6.0,URETHRAL ABSCESS,Urethral abscess,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1996,,BEFORE
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,7.0,POSTINFECTIOUS URETHRAL STRICTURE,Urethral stricture post infection,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2011-11-29,,ONGOING
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-12-15,2011-12-15,BEFORE
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CARDIOSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-12-14,,ONGOING
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ISCHEMIC HEART DISEASE,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-12-14,,ONGOING
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BIOPSY,,PRIOR SURGERY,EXPLORATORY,,2011-09-08,2011-09-08,BEFORE
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02,,ONGOING
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CORONARY ATHEROSCLEROSIS,Arteriosclerosis coronary artery,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-01-10,,ONGOING
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,IHD,Myocardial ischaemia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-01-10,,ONGOING
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MELLITHUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,"CHOLECISTITIS CHRONICAL, WAS PROVIDED LAPAROSCOPIC CHOLECISTECTOMIA",Cholecystitis chronic,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2010-09-29,,BEFORE
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LAPAROCENTESIS OF ASCITIS,Ascites,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02-22,,BEFORE
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CORE BIOPSY OF LIVER  METASTASIS,Metastases to liver,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-02-22,,BEFORE
CO-101-001,CO-101-001-086-005,01086005,086,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NOT Q INFARCTION,Myocardial infarction,MEDICAL HISTORY,,CARDIAC DISORDERS,1997,,BEFORE
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,MENOPAUSA,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1994,,ONGOING
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,SPLENO-PANCREATECTOMY,,PRIOR SURGERY,RESECTION,,2011-01-26,2011-01-26,BEFORE
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1986,,ONGOING
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LEFT THIGH MELANOMA,Malignant melanoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1992-07-27,,BEFORE
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,THYROID CANCER,Thyroid cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1986,,BEFORE
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INTERMITTENT LEFT PELVIC PAINS,Pelvic pain,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-04-18,,ONGOING
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1993,,ONGOING
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,SPLENECTOMY (CONCOMITANT WITH CAUDAL PANCREATECTOMY),Pancreaticosplenectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-01-26,,BEFORE
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,INTERMITTENT ABDOMINAL PAINS GRADE 2,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,CHRONIC GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-16,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,RIGHT INGUINAL HERNIA,Inguinal hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1980,,BEFORE
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ULCEROUS PEPTIC ESOPHAGITIS GRADE 1,Oesophagitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-16,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,ULCEROUS PEPTIC ESOPHAGITIS GRADE 1,Peptic ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-16,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,MODERATE ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,RENAL COLICS,Renal colic,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2008,,BEFORE
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,RENAL COLICS,Renal colic,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-10,,BEFORE
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,SURGERY FOR LEFT INGUINAL HERNIA,Inguinal hernia repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1977,,BEFORE
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DOUBLE DERIVATION,,PRIOR SURGERY,PALLIATIVE INTERVENTION,,2011-05-06,2011-05-06,BEFORE
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,GASTROSTOMY FOR HEMOSTASIS,,PRIOR SURGERY,OTHER,,2011-05-08,2011-05-08,BEFORE
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,TWO HEPATIC NODULES : HEPATIC DOME AND SEGMENT III,,PRIOR SURGERY,RESECTION,,2011-05-06,2011-05-06,BEFORE
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,SINUS TACHYCARDIA,Sinus tachycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAINS (RIGHT HYPOCHONDRIUM),Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03-31,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DYSPEPSIA,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,MOOD ALTERATION : ANXIO-DEPRESSIVE SYNDROME,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-05-06,,BEFORE
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CERVICAL AND LUMBAR ARTHROSIS,Spinal osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1960,,ONGOING
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYSTERECTOMY FOR UTERINE FIBROMA,Uterine leiomyoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1963,,BEFORE
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,SURGERY FOR HIATUS HERNIA,Hernia hiatus repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1999,,BEFORE
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,RIGHT HIP PROSTHESIS INSERTION,Hip arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2009,,ONGOING
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,COMPLETE RIGHT KNEE PROSTHESIS,Knee arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1994,,ONGOING
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,LEFT KNEE PROSTHESIS INSERTION,Knee arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1989,,ONGOING
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL PAINS GRADE 2,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1996,,ONGOING
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INTERMITTENT ABDOMINAL PAINS GRADE 2,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ACUTE PANCREATITIS,Pancreatitis acute,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1998-02,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHOLECYSTECTOMY FOR LITHIASIC CHOLECYSTITIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,1998-06-30,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,INTERMITTENT DORSAL PAINS GRADE 2,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DORSAL ARTHROSIS,Spinal osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1969,,ONGOING
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,PAPILLA'S ADENOMA,Adenoma benign,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1998-03-30,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,MODERATE INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1995,,ONGOING
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,RENAL COLICS,Renal colic,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1970,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1993,,ONGOING
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,APPENDICECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1952,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CALCANEAL TENDON'S SURGERY,Tendon operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1999-01,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,UTERINE POLYP EXCISION,Uterine polypectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1981,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,UTERINE POLYP EXCISION,Uterine polypectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1993,,BEFORE
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1979,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GLAUCOMA,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,2000-03,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ABDOMINAL PAINS (EPIGASTRIUM) GRADE 3,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-19,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,CONSTIPATION GRADE 2,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ASTHENIA GRADE 1,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ANOREXIA GRADE 3,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08-30,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPONATREMIA GRADE 1,Hyponatraemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08-30,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,UNDERNUTRITION,Malnutrition,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,SPHENOIDAL JEGUM MENINGIOMA : RIGHT ANTERIOR FRONTAL OSSEOUS PROSTHESIS,Meningioma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2000-08-14,,BEFORE
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,AGEUSIA GRADE 2,Ageusia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,MOOD ALTERATION : DEPRESSIVE SYNDROME,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2000,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,INSOMNIA GRADE 2,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1984,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INTERMITTENT ARTERIAL HYPERTENSION GRADE 2,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-09-05,,ONGOING
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,BLOCKED IV ACCESS,Poor venous access,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-09-05,,BEFORE
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPOTHYROIDISM (AFTER COMPLETE THYROIDECTOMY FOR GOITER),Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2003,,ONGOING
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAINS (RIGHT HYPOCHONDRIUM),Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INGUINAL HERNIA,Inguinal hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1990,,ONGOING
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,WEIGHT LOSS GRADE 1,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CEPHALIC PANCREATODUODENECTOMY,,PRIOR SURGERY,RESECTION,,2010-10-29,2010-10-29,BEFORE
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NON INSULIN-DEPENDANT DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,CEPHALIC PANCREATODUODENECTOMY,,PRIOR SURGERY,RESECTION,,2011-07-20,2011-07-20,BEFORE
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,INTERMITTENT ABDOMINAL PAINS GRADE 1,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ACUTE PANCREATITIS BALTHAZAR GRADE C,Pancreatitis acute,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04-30,,BEFORE
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,RIGHT ANKLE PHLEBITIS (PLASTER AFTER RIGHT ANKLE FRACTURE),Ankle fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2003-10,,BEFORE
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DYSLIPEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NON INSULIN-DEPENDENT DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ALOPECIA GRADE 1,Alopecia,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1992,,ONGOING
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ATHEROMATOUS STENOSIS OF CELIAC TRUNK (AORTO-HEPATIC  ARTERIAL BY-PASS),Arteriosclerosis,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-07-20,,BEFORE
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ARTERIAL HYPERTENSION (NOT TREATED SINCE 2011),Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,BEFORE
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,RIGHT ANKLE PHLEBITIS (PLASTER AFTER RIGHT ANKLE FRACTURE),Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,2003-10,,BEFORE
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,AURICULAR FIBRILLATION,Atrial fibrillation,MEDICAL HISTORY,,CARDIAC DISORDERS,1995-11,,ONGOING
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ABDOMINAL PAINS,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PERITONITIS,Peritonitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1970,,BEFORE
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,EVENTRATION PROCEDURE,Eventration procedure,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995,,BEFORE
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,UMBILICAL HERNIA REPAIR,Umbilical hernia repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1957,,BEFORE
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1996-05,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,BILIARY STENT,,PRIOR SURGERY,UNKNOWN,,2011-05-31,2011-05-31,BEFORE
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPERTROPHY LEFT VENTRICLE,Left ventricular hypertrophy,MEDICAL HISTORY,,CARDIAC DISORDERS,1993,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010-10,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,POST-TRAUMATIC HEMOPNEUMOTHORAX,Haemothorax,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2005-02,,BEFORE
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,RESECTION OF TENDONS OF THE RIGHT HAND,Tendon operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1986,,ONGOING
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1993,,ONGOING
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,BILIARY STENT,,PRIOR SURGERY,UNKNOWN,,2011-06-15,2011-06-15,BEFORE
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,COURSE OF SUS-OMBILICAL TUMEFACTION,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1999-10,,ONGOING
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,EPIGASTRIAL PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-07,,BEFORE
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,HYPERLEUCOCYTOSIS,Leukocytosis,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-26,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,EXTRASYSTOLE,Extrasystoles,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-03-16,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,TACHYCARDIA,Tachycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,2010-03-16,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,HYPOTHYRODISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2010-05-15,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,ABDOMINAL PAINS,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,ASTHENIA,Asthenia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,Systemic inflammatory response syndrome,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2005-07,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HEPATITIS B,Hepatitis B,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2007-07,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TUBERCULOSIS OF THE LEFT SHOULDER,Joint tuberculosis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,1950-03,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CRANIAL TRAUMATISM,Craniocerebral injury,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1999-12,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,FRACTURES OF RIBBS,Rib fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2000-12,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,FRACTURES OF RIBS,Rib fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",1990-12,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,DISCAL HERNIA,Intervertebral disc protrusion,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1990-09,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,EXERESIS OF AN ABDOMINAL SIDE TUMOR,Abdominal neoplasm,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1981-03,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,CARCINOMA OF THE LEFT TESTIS,Testis cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1982-09,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2006-07-19,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PNEUMOTHORAX,Pneumothorax,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1999-12,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1977-01,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1978-02,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ALLLERGIC RHINITIS,Rhinitis allergic,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2007-07-30,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,SLEEPY APNOEA,Sleep apnoea syndrome,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2007,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1995-09,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,TRANSITIONAL CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1967-03,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,MENISCECTOMY,Meniscus removal,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1983-03,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ARTERIAL HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2008-10,,ONGOING
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEFT LOWER LIMB PHLEBITIS,Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,1986-02,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,LEFT LOWER LIMB PHLEBITIS,Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,1988-07,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,PHLEBITIS,Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,1971-06,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,RIGHT LOWER LIMB PHLEBITIS,Phlebitis,MEDICAL HISTORY,,VASCULAR DISORDERS,1983-05,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,BILATERAL VARIX,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1977-05,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,BILATERAL VARIX,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1980-02,,BEFORE
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,BILATERAL VARIX,Varicose vein,MEDICAL HISTORY,,VASCULAR DISORDERS,1997-07,,BEFORE
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,GASTROINTESTINAL PAIN,Gastrointestinal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-09,,ONGOING
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008-10,,ONGOING
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANGINA PECTORIS,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERLIPEDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ARTROPLASTIC IN BOTH HIPS,Hip arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2001,,BEFORE
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,HYPOTHYREOS,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,PAIN IN ABDOMEN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,Chronic obstructive pulmonary disease,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2009,,ONGOING
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DIAGNOSTIC BIOPSY,,PRIOR SURGERY,OTHER,,2010-09-13,2010-09-13,BEFORE
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GASTROINTESTINAL REFLUX DISEASE,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,,,ONGOING
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ARTHRITIS,Arthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SQUAMOUS CELL CARCINOMA,Squamous cell carcinoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",,,BEFORE
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,CHOLECYSTECTOMY,,PRIOR SURGERY,EXPLORATORY,,2011-07-18,2011-07-18,BEFORE
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1999,,ONGOING
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-02,,ONGOING
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,PENICILLIN,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,,,ONGOING
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,PROSTATE CANCER,Prostate cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1999,,BEFORE
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-03,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-03,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,GASTRIC HYPOMOTILITY,Gastric hypomotility,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-17,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,GASTRITIS,Gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GASTROESOPHAGEAL REFLUX DISEASE/EARLY SATIETY,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-19,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,RECTAL TEAR,Rectal fissure,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,GASTROESOPHAGEAL REFLUX DISEASE/EARLY SATIETY,Early satiety,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-19,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,GENERAL PAIN,Pain,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CHOLELITHIASIS,Cholelithiasis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,LOSS OF APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-19,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,LEFT CARPAL TUNNEL RELEASE,Carpal tunnel decompression,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ELBOW SURGERY,Elbow operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,HEEL SURGERY,Foot operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,KNEE REPLACEMENT SURGERY,Knee arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,BACK SURGERY,Surgery,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPOTHYROID,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1994,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-01,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02-06,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIVERTICULOSIS,Diverticulum,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-20,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-01,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MUSCLE SPASMS,Muscle spasms,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,BEFORE
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1992,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,ANGINA PECTORIS,Angina pectoris,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,PAIN - ABDOMINAL,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-02,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2012-02,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,LEFT GROIN PAIN,Groin pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-02,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,APPENDECTOMY,Appendicectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000,,BEFORE
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,CORONARY ARTERY BYPASS GRAFT,Coronary artery bypass,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2007,,ONGOING
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,VASECTOMY,Vasectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1987,,BEFORE
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CORONARY ARTERY DISEASE,Coronary artery disease,MEDICAL HISTORY,,CARDIAC DISORDERS,2011-04-26,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2009-09-28,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CATARACT,Cataract,MEDICAL HISTORY,,EYE DISORDERS,2008-04-21,,BEFORE
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,GERD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-03,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,DELAYED GASTRIC EMPTYING,Impaired gastric emptying,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-10,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,BEFORE
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,NONCARDIAC CHEST PAIN,Non-cardiac chest pain,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,BILATERAL LOWER EXTREMITY EDEMA,Oedema peripheral,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-13,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-04,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006-12-14,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,DIABETES MELLITUS TYPE 1,Type 1 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1963,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,LOW BACK PAIN (INTERMITTENT),Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,OSTEOARTHRITIS,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006-09-01,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,SENSORY NEUOPATHY (FEET),Peripheral sensory neuropathy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,URINARY RETENTION,Urinary retention,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-06-10,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ERECTILE DYSFUNCTION,Erectile dysfunction,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CATARACT REMOVAL LEFT EYE,Cataract operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-08-14,,BEFORE
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CATARACT REMOVAL RIGHT EYE,Cataract operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2008-09-22,,BEFORE
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,YAG POSTERIOR CAPSULOTOMY (LEFT EYE),Posterior capsulotomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2010-10-08,,BEFORE
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006-12-14,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-10-25,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,RIGHT TINNITUS,Tinnitus,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,2010-04-02,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,MACULAR DENGENERATION,Macular degeneration,MEDICAL HISTORY,,EYE DISORDERS,1990,,BEFORE
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,BOWEL URGENCY,Defaecation urgency,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,DIVERTICULOSIS,Diverticulum,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,GASTRIC REFLUX,Reflux gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2010-12-02,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,GENERALIZED FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ABNORMAL GLUCOSE,Blood glucose abnormal,MEDICAL HISTORY,,INVESTIGATIONS,2006,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,NON-SPECIFIC ECG,Electrocardiogram abnormal,MEDICAL HISTORY,,INVESTIGATIONS,2007,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,LOW VITAMIN D,Vitamin D decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-02-22,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEVI(LEFT ABDOMINAL WALL AND LEFT CHEST CLAVICLE),Melanocytic naevus,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2008-11-12,,BEFORE
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PROSTATE CANCER WITH SEED IMPLANT,Prostate cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1997,,BEFORE
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIZZINESS,Dizziness,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010-04-02,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-08-06,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,LEFT LOWER QUANDRANT ABDOMINAL PAIN,Abdominal pain lower,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DRY MOUTH,Dry mouth,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-29,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,BEFORE
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,UMBILICAL HERNIA,Umbilical hernia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,BEFORE
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,UNINTENTIONAL WEIGHT LOSS,Abnormal loss of weight,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09-14,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPOVITAMINOSIS D,Hypovitaminosis,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08-10,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,SMOKERS COUGH,Cough,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-29,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,BLOATING,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,EXCESSIVE GAS,Flatulence,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,OVERACTIVE BLADDER,Hypertonic bladder,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PARTIAL HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1996,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,INTERMITTENT TACYCARDIA,Tachycardia,MEDICAL HISTORY,,CARDIAC DISORDERS,2012-01-31,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,BLOATING,Abdominal distension,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,STOMACH PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,EXCESSIVE GAS,Flatulence,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,GASTRIC REFLUX,Reflux gastritis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-17,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-01-20,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,TRANSIENT ISCHEMIC ATTACK,Transient ischaemic attack,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2001-08-13,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPERTROPHY OF THE PROSTATE,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1971,,ONGOING
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1966,,ONGOING
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1994,,ONGOING
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CHONDRCALCINOSIS,Chondrocalcinosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007-01-02,,ONGOING
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,OSTEOARTHRITIS,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007-01-02,,ONGOING
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CAROTID ARTHEROSCLEROSIS,Carotid arteriosclerosis,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,RIGHT RENAL ARTERY STENOSIS,Renal artery stenosis,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,PULMONARY EMBOLI,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-20,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ABDOMINAL AORTIC ANEURYSM REPAIR,Aortic aneurysm repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1996,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,LEFT CAROTID ENDARTERECTOMY,Carotid endarterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1999-06-29,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,CHOLECYSTECTOMY,Cholecystectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-07-18,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PTCA WITH STENT,Coronary angioplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PTCA WITH STENT,Coronary arterial stent insertion,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ECRP-STENT PLACEMENT,Stent placement,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-05-04,,BEFORE
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1994,,ONGOING
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,"ALLERGY TO MORPHINE, PENACILLIN, ERYTHROMYCIN, CIPRO",Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,"ALLERGY TO MORPHINE, PENACILLIN, ERYTHROMYCIN, CIPRO",Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,"ALLERGY TO MORPHINE, PENACILLIN, ERYTHROMYCIN, CIPRO",Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1998,,ONGOING
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,BLADDER CANCER,Bladder cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",1998,,BEFORE
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ABDOMINAL PAIN FROM PANCREATIC CANCER,Cancer pain,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07,,ONGOING
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-07-28,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,ERCP,,PRIOR SURGERY,OTHER,,2012-01-12,2012-01-12,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,AQUIRED TEAR DUCT OCCLUSION,Dacryostenosis acquired,MEDICAL HISTORY,,EYE DISORDERS,2009-03,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,MACULAR DEGENERATION,Macular degeneration,MEDICAL HISTORY,,EYE DISORDERS,1993,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,SHARP PAIN IN STOMACH AFTER EATING EVENING MEALS,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,INTERMITTENT CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,INTERNAL HEMORRHOIDS,Haemorrhoids,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,BILATERAL FOOT CELLULITIS,Cellulitis,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2005-11-09,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,MILD VERTEBRAL COMPRESSION FRACTURES,Spinal compression fracture,MEDICAL HISTORY,,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2003-07-15,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ERCP WITH STENT,Endoscopic retrograde cholangiopancreatography,MEDICAL HISTORY,,INVESTIGATIONS,2012-01-12,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-12,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,TYPE 2 DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LOW BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1940,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,RIGHT TROCHANTERIC BURSITIS,Bursitis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-03-16,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DISC DEGENTERATION/SPONDYLOSIS L4-L5,Intervertebral disc degeneration,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2003-07-15,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,OSTEOARTHRITIS,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1992,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,OSTEOPENIA,Osteopenia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007-07-18,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DISC DEGENTERATION/SPONDYLOSIS L4-L5,Spinal osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2003-07-15,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,CHANGES IN TASTE OF FOOD,Dysgeusia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,TRANSIENT ISCHEMIC ATTACK,Transient ischaemic attack,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,1998,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006-05-17,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ERCP WITH STENT,Stent placement,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2012-01-12,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,TEAR DUCT STENT PLACEMENT,Stent placement,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2009-03,,BEFORE
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ERCP,,PRIOR SURGERY,UNKNOWN,,2011-10-20,2011-10-20,BEFORE
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ESOPHAGOGASTRODUODENOSCOPY WITH STENT REMOVAL,,PRIOR SURGERY,UNKNOWN,,2011-12-09,2011-12-09,BEFORE
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,LAPAROSCOPY WITH PERITONEAL CYTOLOGY,,PRIOR SURGERY,UNKNOWN,,2012-01-26,2012-01-26,BEFORE
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,PORT PLACEMENT,,PRIOR SURGERY,UNKNOWN,,2012-02-17,2012-02-17,BEFORE
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,UPPER ENDOSCOPY WITH FNA,,PRIOR SURGERY,UNKNOWN,,2011-11-10,2011-11-10,BEFORE
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09,,ONGOING
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,POOR APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LOW BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,HYPOTHYROIDISM,Hypothyroidism,MEDICAL HISTORY,,ENDOCRINE DISORDERS,1982,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,BILATERAL CATARACTS,Cataract,MEDICAL HISTORY,,EYE DISORDERS,2010,,BEFORE
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-03-19,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,INTERMITTENT CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-03-25,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,INTERMITTENT NAUCSEA/VOMITING,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-03,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,INTERMITTENT NAUCSEA/VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-03,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,INTERMITTENT HERPES ZOSTER,Herpes zoster,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2010,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-01,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,TYPE 2 DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,VITAMIN B12 DEFICIENCY,Vitamin B12 deficiency,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-03,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,VITAMIN D DEFICIENCY,Vitamin D deficiency,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,PERIPHERAL NEUROPATHY,Neuropathy peripheral,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,STRESS,Stress,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1982,,ONGOING
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,LUMPECTOMY LEFT BREAST,Breast lump removal,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1959,,BEFORE
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,CARPAL TUNNEL SURGERY,Carpal tunnel decompression,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006,,BEFORE
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ORAL SURGERY,Oral surgery,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-07,,BEFORE
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,TRIGGER FINGER RELEASE,Tendon sheath incision,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1970,,BEFORE
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,PAIN - ABDOMINAL AREA,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,GERD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,"URINARY DIFFICULTIES, INCONTINENCE",Urinary incontinence,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,SMOKING,Tobacco user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,2011,,ONGOING
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,11.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,GASTROESOPHAGEAL REFLUX DISEASE,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-11,,BEFORE
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,VOMITING,Vomiting,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-11,,BEFORE
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,CHILLS,Chills,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-11,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-11,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,13.0,FEVER,Pyrexia,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-11,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,DYSLIPIDEMIA,Dyslipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,12.0,JOINT PAIN,Arthralgia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-11,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,LUMBAR SPINAL FUSION (SURGICAL),Spinal fusion surgery,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1971,,ONGOING
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2001,,ONGOING
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08-15,,ONGOING
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010,,ONGOING
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY,Endoscopic retrograde cholangiopancreatography,MEDICAL HISTORY,,INVESTIGATIONS,2011-08-17,,BEFORE
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-08-15,,ONGOING
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,SILICONE BREAST IMPLANTS,Breast prosthesis user,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1985,,ONGOING
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,C-SECTION,Caesarean section,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1981,,BEFORE
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,C-SECTION,Caesarean section,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1983,,BEFORE
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,CELIAC PLEXUS BLOCK/NEUROLYSIS,Neurolysis,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2012-09-19,,BEFORE
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PLASTIC STENT INSERTION,Stent placement,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-08-17,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,"PANCREATIC TAIL MASS, EUS",,PRIOR SURGERY,OTHER,,2011-09-09,2011-09-09,BEFORE
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,RIGHT PARAAORTIC SOFT TISSUE MASS,,PRIOR SURGERY,OTHER,,2011-10-11,2011-10-11,BEFORE
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,ULTRASOUND CELIAC PLEXUS BLOCKADE,,PRIOR SURGERY,OTHER,,2011-09-08,2011-09-08,BEFORE
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ULTRASOUND NEEDLE CORE BIOPSY,,PRIOR SURGERY,OTHER,,2011-09-08,2011-09-08,BEFORE
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07-25,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,STOMACH ULCERS,Gastric ulcer,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-25,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ALLERGY TO HYDROMORPHONE,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,HEPATITIS C,Hepatitis C,MEDICAL HISTORY,,INFECTIONS AND INFESTATIONS,2003,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-07-25,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LEFT HIP WEAKNESS,Muscular weakness,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,DIZZINESS UPON STANDING,Dizziness postural,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,FOOT DROP,Peroneal nerve palsy,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-08-25,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ENLARGED PROSTATE,Prostatomegaly,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,RIGHT ANKLE RASH,Rash,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CELIAC PLEXUS BLOCK,Local anaesthesia,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-09-09,,ONGOING
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-15,,ONGOING
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-21,,ONGOING
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CODEINE,Drug hypersensitivity,MEDICAL HISTORY,,IMMUNE SYSTEM DISORDERS,1996,,ONGOING
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10-20,,ONGOING
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-08,,ONGOING
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-06,,ONGOING
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10-20,,ONGOING
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,SWEATING SPELLS,Hyperhidrosis,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12-06,,ONGOING
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,MENOPAUSE,Menopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1997,,ONGOING
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,EPIGASTRIC PAIN,Abdominal pain upper,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-15,,ONGOING
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-02-01,,ONGOING
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,BENIGN PROSTATIC HYPERTROPHY,Benign prostatic hyperplasia,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CBD STENTING TO RELIEVE JAUNDICE,,PRIOR SURGERY,OTHER,,2012-03-06,2012-03-06,BEFORE
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-24,,ONGOING
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HEART MURMUR,Cardiac murmur,MEDICAL HISTORY,,INVESTIGATIONS,1952-10,,ONGOING
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2012-03-06,,ONGOING
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,MULTILEVEL DEGENERATIVE DISC DISEASE,Intervertebral disc degeneration,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1992,,ONGOING
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,MILD TO MODERATE LUMBAR SPONDYLOSIS,Spinal osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1992,,ONGOING
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,TUBAL LIGATION,Female sterilisation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1976,,BEFORE
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007-02,,ONGOING
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-10,,ONGOING
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GLAUCOMA,Glaucoma,MEDICAL HISTORY,,EYE DISORDERS,2009,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,GERD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DEGENERATIVE JOINT DISEASE,Osteoarthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,SPINAL STENOSIS,Spinal column stenosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HISTORY OF BELLS PALSY,VIIth nerve paralysis,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2009-03,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,RIGHT ANKLE SURGERY,Ankle operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BLIATERAL CARPAL TUNNEL SURGERY,Carpal tunnel decompression,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,LEFT KNEE REPLACEMENT,Knee arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2004,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,RIGHT KNEE SURGERY,Knee operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2006,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BILATERAL SHOULDER SURGERY,Shoulder operation,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2003,,BEFORE
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,SURGICAL SPINAL FUSION,Spinal fusion surgery,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2009,,BEFORE
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,MACROCYTIC ANEMIA,Anaemia macrocytic,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,RIGHT HEMICOLECTOMY FOR CECYL POLYP,Colonic polyp,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1999,,BEFORE
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,INTERMITTENT CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1991,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,BILATERAL LOWER EXTREMITY EDEMA,Oedema peripheral,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,1998,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,NASH STEATOHEPATITIS,Non-alcoholic steatohepatitis,MEDICAL HISTORY,,HEPATOBILIARY DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2009,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,INTERMITTENT GOUT,Gout,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006-06,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PSORIATIC ARTHRITIS,Psoriatic arthropathy,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006-06,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PERIPHERAL NEUROPATHY,Neuropathy peripheral,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2008,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2010-12,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,POST MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1990,,ONGOING
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,INCISIONAL HERNIA REPAIR,Incisional hernia repair,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2002-05,,BEFORE
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-08,,BEFORE
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,INTERMITTENT DIARRHEA,Diarrhoea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,GERD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,60 LB INTENTIONAL WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2010,,BEFORE
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06,,BEFORE
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,IRREGULAR MENSES,Menstruation irregular,MEDICAL HISTORY,,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HOT FLASHES,Hot flush,MEDICAL HISTORY,,VASCULAR DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-16,,ONGOING
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2012-01-16,,ONGOING
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,DYSPEPSIA,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-29,,ONGOING
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PAIN - BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PAIN - NECK,Neck pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,PERIPHERAL NEUROPATHY,Neuropathy peripheral,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2011-04,,ONGOING
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,,,ONGOING
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LOWER BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,,,ONGOING
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,BASAL CELL CARCINOMA,Basal cell carcinoma,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04,,BEFORE
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,MILD CVA,Cerebrovascular accident,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,,,BEFORE
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ASTHMA,Asthma,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",,,ONGOING
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PULMONARY EMBOLISM,Pulmonary embolism,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",1999,,ONGOING
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,BENIGN ESSENTIAL HYPERTENSION,Essential hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,,,ONGOING
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,DIVERTING COLOSTOMY,,PRIOR SURGERY,OTHER,,2011-07-18,2011-07-18,BEFORE
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,GERD,Gastrooesophageal reflux disease,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,POST-MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,,,ONGOING
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,COLOSTOMY,Colostomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2011-07-18,,ONGOING
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,TOTAL KNEE REPLACEMENT,Knee arthroplasty,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,2000,,BEFORE
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ATRIAL FIBRILLATION,Atrial fibrillation,MEDICAL HISTORY,,CARDIAC DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,EARLY SATIETY,Early satiety,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DIABETES MELLITUS,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,RHEUMATOID ARTHRITIS,Rheumatoid arthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010,,ONGOING
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ABDOMINAL PAIN RADIATING TO BACK,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN RADIATING TO BACK,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,EMPHYSEMA,Emphysema,MEDICAL HISTORY,,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-03,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-30,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-06-30,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-03,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-03,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERLIPIDIMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIABETES MELLITUS NID,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-30,,ONGOING
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,"MALIGNANT NEOPLASM BLADDER, UNSPECIFIED",Bladder cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2006-03-30,,BEFORE
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-26,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ASCITES/ PARACENTESIS,Ascites,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HEARTBURN,Dyspepsia,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-25,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NAUSEA,Nausea,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-26,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,ANOREXIA/ WEIGHT LOSS,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09-26,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,BACK PAIN,Back pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-16,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-09-21,,ONGOING
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-09-19,,ONGOING
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,RENAL DYSPLASIA,Renal dysplasia,MEDICAL HISTORY,,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2010-12,,ONGOING
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-15,,ONGOING
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,HYPERCALCEMIA,Hypercalcaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-19,,ONGOING
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-12-21,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,HEARING LOSS,Deafness,MEDICAL HISTORY,,EAR AND LABYRINTH DISORDERS,2011-08,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CATARACTS,Cataract,MEDICAL HISTORY,,EYE DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DRY MOUTH,Dry mouth,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-05-03,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,EDEMA LOWER EXTREMITIES,Oedema peripheral,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2009,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,WEIGHT LOSS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-01,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,LOSS OF APPETITE,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-06,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09-12,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ARTHRITIS,Arthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,OSTEOPOROSIS,Osteoporosis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2006,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,NUMBNESS IN TOES,Hypoaesthesia,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2009-11,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-10-17,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,URINARY FREQUENCY,Pollakiuria,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2010-11,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HAIR LOSS,Alopecia,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-03,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,NAIL CHANGES,Nail disorder,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-08-03,,ONGOING
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HYSTERECTOMY,Hysterectomy,MEDICAL HISTORY,,SURGICAL AND MEDICAL PROCEDURES,1976,,BEFORE
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,13.0,ANEMIA,Anaemia,MEDICAL HISTORY,,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,18.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,17.0,DRY MOUTH,Dry mouth,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-12-13,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,16.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,15.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12-13,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,11.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,HYPERCHOLESTEROLEMIA,Hypercholesterolaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2005-05,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,ARTHRITIS BILATERAL SHOULDERS,Arthritis,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2007-04-03,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,14.0,RIGHT SHOULDER PAIN,Musculoskeletal pain,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2005,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,COLON CANCER,Colon cancer,MEDICAL HISTORY,,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2006-12-28,,BEFORE
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,12.0,INSOMNIA,Insomnia,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,19.0,URINARY FREQUENCY,Pollakiuria,MEDICAL HISTORY,,RENAL AND URINARY DISORDERS,2011-12,,BEFORE
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,HAIR LOSS,Alopecia,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,DRY SKIN,Dry skin,MEDICAL HISTORY,,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,POST-MENOPAUSAL,Postmenopause,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1950,,ONGOING
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2007-04,,ONGOING
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,RETINOPATHY,Retinopathy,MEDICAL HISTORY,,EYE DISORDERS,2002,,ONGOING
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,INTERMITTENT MOUTH SORES,Stomatitis,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,1982,,ONGOING
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1997,,ONGOING
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,TYPE I DIABETES,Type 1 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-12,,ONGOING
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,TYPE II DIABETES,Type 2 diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,1997,,BEFORE
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,STROKE,Cerebrovascular accident,MEDICAL HISTORY,,NERVOUS SYSTEM DISORDERS,2005-07,,BEFORE
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,DENTURES,Denture wearer,MEDICAL HISTORY,,SOCIAL CIRCUMSTANCES,1982,,ONGOING
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,HYPERTENSION,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,1997,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,15.0,LIVER BIOPSY,,PRIOR SURGERY,OTHER,,2011-11-17,2011-11-17,BEFORE
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,14.0,PANCREAS BIOPSY,,PRIOR SURGERY,OTHER,,2011-10-28,2011-10-28,BEFORE
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,12.0,ABDOMINAL PAIN,Abdominal pain,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,11.0,CONSTIPATION,Constipation,MEDICAL HISTORY,,GASTROINTESTINAL DISORDERS,2011-11-04,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,FATIGUE,Fatigue,MEDICAL HISTORY,,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,13.0,WEIGHT LOSS IN PAST 6 MONTHS,Weight decreased,MEDICAL HISTORY,,INVESTIGATIONS,2011-07,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,ANOREXIA,Decreased appetite,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,DIABETES,Diabetes mellitus,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-09,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,HYPERLIPIDEMIA,Hyperlipidaemia,MEDICAL HISTORY,,METABOLISM AND NUTRITION DISORDERS,2011-10-01,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,JOINT PAIN- R SHOULDER PAIN,Arthralgia,MEDICAL HISTORY,,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,ANXIETY,Anxiety,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-09,,BEFORE
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,DEPRESSION,Depression,MEDICAL HISTORY,,PSYCHIATRIC DISORDERS,2011-10-25,,ONGOING
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,HTN,Hypertension,MEDICAL HISTORY,,VASCULAR DISORDERS,2011-09-01,,ONGOING
